



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

| | | |
|--|-----------|---|
| (51) International Patent Classification ⁵ : C12N 15/29, C07K 7/10 C12N 15/82, A01N 65/00 A01H 5/00, C12N 5/10, 1/21 | A1 | (11) International Publication Number: WO 93/05153 (43) International Publication Date: 18 March 1993 (18.03.93) |
| (21) International Application Number: PCT/GB92/01570 (22) International Filing Date: 27 August 1992 (27.08.92) (30) Priority data: 9118523.1 29 August 1991 (29.08.91) GB 9203038.6 13 February 1992 (13.02.92) GB 9213526.8 25 June 1992 (25.06.92) GB (71) Applicant (for all designated States except US): IMPERIAL CHEMICAL INDUSTRIES PLC [GB/GB]; Imperial Chemical House, Millbank, London SW1P 3JF (GB). (72) Inventors; and (75) Inventors/Applicants (for US only) : BROEKAERT, Willem, Frans [BE/BE]; Levoldlaan 18, B-1700 Dilbeek (BE). CAMMUE, Bruno, Philippe, Angelo [BE/BE]; J.B. Woutersstraat 109A, B-1652 Alsemberg (BE). OSBORN, Rupert, William [GB/GB]; 36 Warwick Road, Twicken- ham, Middlesex TW2 6SW (GB). REES, Sarah, Bronwen [GB/GB]; 32 Micheldever Way, Forest Park, Bracknell, Berkshire RG12 3XX (GB). TERRAS, Franky, Ray- mond, Gerard [BE/BE]; Schaagstraat 96, B-8570 Anze- gem (BE). VANDERLEYDEN, Jozef [BE/BE]; Kastan- jelaan 12, B-3001 Heverlee (BE). | | (74) Agent: ROBERTS, Timothy, Wace; Imperial Chemical In- dustries plc, ICI Group Patent Department, P.O. Box 6, Bessemer Road, Welwyn Garden City, Herts AL7 1HD (GB). (81) Designated States: AU, BB, BG, BR, CA, CS, FI, HU, JP, KP, KR, LK, MG, MN, MW, NO, PL, RO, RU, SD, US, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, SN, TD, TG). Published <i>With international search report.</i> |
| (54) Title: BIOCIDAL PROTEINS (57) Abstract <p>Biocidal proteins isolated from seeds have been characterized, in particular proteins isolated from members of the Brassicaceae, Compositae and Leguminosae families including <i>Raphanus</i>, <i>Brassica</i>, <i>Sinapis</i>, <i>Arabidopsis</i>, <i>Dahlia</i>, <i>Cnicus</i>, <i>Lathyrus</i> and <i>Clitoria</i>. The proteins show a wide range of antifungal activity and some are active against Gram-positive bacteria. All share a common amino acid sequence. DNA encoding the proteins has been isolated and incorporated into vectors. Plants transformed with this DNA may be produced. The proteins find commercial application as antifungal or antibacterial agents; transformed plants will show increased disease-resistance.</p> | | |

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

| | | | | | |
|----|--------------------------|----|---------------------------------------|----|--------------------------|
| AT | Austria | FI | Finland | MN | Mongolia |
| AU | Australia | FR | France | MR | Mauritania |
| BB | Barbados | GA | Gabon | MW | Malawi |
| BE | Belgium | GB | United Kingdom | NL | Netherlands |
| BF | Burkina Faso | GN | Guinea | NO | Norway |
| BG | Bulgaria | GR | Greece | NZ | New Zealand |
| BJ | Benin | HU | Hungary | PL | Poland |
| BR | Brazil | IE | Ireland | PT | Portugal |
| CA | Canada | IT | Italy | RO | Romania |
| CF | Central African Republic | JP | Japan | RU | Russian Federation |
| CG | Congo | KP | Democratic People's Republic of Korea | SD | Sudan |
| CH | Switzerland | KR | Republic of Korea | SE | Sweden |
| CI | Côte d'Ivoire | LI | Liechtenstein | SK | Slovak Republic |
| CM | Cameroon | LK | Sri Lanka | SN | Senegal |
| CS | Czechoslovakia | LU | Luxembourg | SU | Soviet Union |
| CZ | Czech Republic | MC | Monaco | TD | Chad |
| DE | Germany | MG | Madagascar | TG | Togo |
| DK | Denmark | ML | Mali | UA | Ukraine |
| ES | Spain | | | US | United States of America |

BIOCIDAL PROTEINS

This invention relates to biocidal proteins, processes for their manufacture and use, and DNA sequences coding for them. In particular, it relates to antimicrobial proteins isolated from seeds such as those of members of the Brassicaceae, Compositae or Leguminosae families.

In this context, antimicrobial proteins are defined as proteins possessing at least one of the following activities: antifungal activity (which may include anti-yeast activity); antibacterial activity. Activity includes a range of antagonistic effects such as partial inhibition or death.

The Brassicaceae is a large family of herbs and shrubs which grow widely in tropical, sub-tropical and temperate regions. The Family Brassicaceae is also known as the "Cruciferae". Raphanus sativus (radish) belongs to this family and is cultivated widely as a vegetable.

Dahlia belongs to the Compositae and has been extensively cultivated as an ornamental garden plant. A number of hybrids are commercially available, belonging to the Dahlia merckii or Dahlia variabilis species. Cnicus benedictus, another Compositae, is a native plant of the Mediterranean regions and was once used as a tonic and a cure for gout.

Lathyrus and Clitoria belong to the Leguminosae family. Lathyrus has been extensively cultivated as an ornamental garden plant, the most widely known being the sweet pea plant, Lathyrus odoratus. The genus Clitoria is less well known to European gardeners; Clitoria ternatea was originally introduced from the East Indies in the

1800s.

Although plants normally grow on substrates that are extremely rich in fungal organisms, infection remains a rare event. To keep out potential invaders, plants produce a wide array of antifungal compounds, either in a constitutive or an inducible manner. The best studied of these are phytoalexins which are secondary metabolites with a broad antimicrobial activity spectrum that are specifically synthesised upon perception of appropriate defence-related signal molecules. The production of phytoalexins depends on the transcriptional activation of a series of genes encoding enzymes of the phytoalexin biosynthetic pathway. During the last decade, however, it has become increasingly clear that some plant proteins can play a more direct role in the control of phytopathogenic fungi. Several classes of proteins with antifungal properties have now been identified, including chitinases, beta-1,3-glucanases, chitin-binding lectins, zeamatin, thionins and ribosome-inactivating proteins.

These proteins have gained considerable attention as they could potentially be used as biocontrol agents. The chitinases and beta-1,3-glucanases have weak activities by themselves, and are only inhibitory to plant pathogens when applied in combination (Mauch et al, 1988, Plant Physiol, 88, 936-942). The chitin-binding lectins can also be classified as rather weak antifungal factors (Broekaert et al, 1989, Science, 245, 1100-1102; Van Parijs et al, 1991, Planta, 183, 258-264). Zeamatin is a more

potent antifungal protein but its activity is strongly reduced by the presence of ions at physiological concentrations (Roberts and Selitnermikoff, 1990, G Gen Microbiol, 136, 2150-2155). Finally, thionins and ribosome-inactivating proteins are potentially hazardous since they are known to be toxic for human cells (Carrasco et al, 1981, Eur J Biochem, 116, 185-189; Vernon et al, 1985, Arch Biochem Biophys, 238, 18-29; Stirpe and Barbieri, 1986, FEBS Lett, 195, 1-8).

We have now purified a new class of potent antimicrobial proteins with broad spectrum activity against plant pathogenic fungi and with some antibacterial activity, moderate sensitivity to ions and apparent low toxicity for cultured human cells.

According to the present invention, we provide antimicrobial proteins capable of being isolated from seeds and in particular from members of the Brassicaceae, the Compositae or the Leguminosae families including Raphanus, Brassica, Sinapis, Arabidopsis, Dahlia, Cnicus, Lathyrus or Clitoria.

In further aspects, this invention comprises a vector containing a DNA sequence coding for a protein according to the invention. The DNA may be cloned or transformed into a biological system allowing expression of the encoded protein.

The invention also comprises plants transformed with recombinant DNA encoding an antimicrobial protein according to the invention.

The invention also comprises a process of combating fungi or bacteria whereby they are exposed to the proteins according to the invention.

A new class of potent antimicrobial proteins has been isolated from seeds of the Brassicaceae, the Compositae, and the Leguminosae. Similar proteins may be found in other plant families, genera and species. The class includes proteins which share a common amino acid sequence and which show activity against a range of plant pathogenic fungi.

The antimicrobial proteins isolated from seeds of Raphanus sativus (radish) include two protein factors, hereafter called Rs-AFP1 (Raphanus sativus - Antifungal Protein 1) and Rs-AFP2 (Raphanus sativus - Antifungal Protein 2) respectively. Both are oligomeric proteins, composed of identical 5 kDa subunits. Both proteins are highly basic and have pI values above 10. Similar antifungal proteins have been isolated from other Brassicaceae, including Brassica napus (Bn-AFPs), Brassica rapa (Br-AFPs), Sinapis alba (Sa-AFPs) and Arabidopsis thaliana (At-AFP1).

The antimicrobial proteins isolated from seeds of Dahlia and Cnicus include four protein factors, hereafter called Dm-AMP1 (Dahlia merckii - Antimicrobial Protein 1), Dm-AMP2 (Dahlia merckii - Antimicrobial Protein 2), Cb-AMP1 (Cnicus benedictus - Antimicrobial Protein 1) and Cb-AMP2 (Cnicus benedictus - Antimicrobial Protein 2) respectively. The Dm-AMP proteins may be isolated from seed of the Dahlia genus. The Cb-AMP proteins may be isolated from seed of the Cnicus genus. All four proteins are closely related and are composed of 5 kDa subunits arranged as oligomeric structures. All four proteins are highly basic.

The antimicrobial proteins isolated from seeds

of Lathyrus and Clitoria include three protein factors, hereafter called Lc-AFP (Lathyrus cicera - Antifungal Protein), Ct-AMP1 (Clitoria ternatea - Antimicrobial Protein 1) and Ct-AMP2 (Clitoria ternatea - Antimicrobial Protein 2) respectively. Lc-AFP may be isolated from seed of the Lathyrus genus. The Ct-AMP proteins may be isolated from seed of the Clitoria genus. All three proteins are composed of 5 kDa subunits arranged as oligomeric structures and are highly basic.

N-terminal amino acid sequence determination has shown that the above proteins isolated from the Brassicaceae, Compositae and Leguminosae are closely related and can be classified as a single protein family. Between the different plant families, the protein sequences are approximately 50% identical. These sequences enable manufacture of the proteins by chemical synthesis using a standard peptide synthesiser.

The antimicrobial proteins are partially homologous to the predicted protein products of the Fusarium-induced genes pI39 and pI230 in pea (Pisum sativum - a member of the Leguminosae family) as described by Chiang and Hadwiger, 1991 (Mol Plant Microbe Interact, 4, 324-331). This homology is shared with the predicted protein product of the pSAS10 gene from cowpea (Vigna unguiculata - another legume) as described by Ishibashi et al (Plant Mol Biol, 1990, 15, 59-64). The antimicrobial proteins are also partially homologous with the predicted protein product of gene pI322 in potato (Solanum tuberosum - a member of the Solanaceae family) as described by Stiekema et al, 1988 (Plant Mol Biol, 11, 255-269). Nothing

is known about the biological properties of the proteins encoded by genes pI39, pI230, pSAS10 or pI322 as only the cDNA has been studied. However, the pI39, pI230 and pI322 genes are switched on after challenge to the plant by a disease or other stress. It has been proposed that the pSAS10 gene encodes a protein involved in germination. Due to their sequence similarity with the antimicrobial proteins of the invention, the proteins encoded by the pI39, pI230, pSAS10 or pI322 genes may be useful as fungicides or as antibiotics.

The antimicrobial protein sequences show a lower degree of partial homology with the sequences of a group of small α -amylase inhibitors found in the following members of the Gramineae: sorghum (Bloch and Richardson, 1991, FEBS Lett, 279:101-104), wheat (Colitta *et al*, 1990, FEBS Lett, 270:191-194) and barley (Mendez *et al*, 1990 Eur J Biochem, 194:533-539). Such proteins, including SI α 2 from sorghum and γ -1-purothionin from wheat, are known to inhibit insect α -amylase and are toxic to insect larvae. It is not known if these α -amylase inhibitors show any antifungal or other antimicrobial activity: no other data on their biological activity has been reported. Due to their sequence similarity with the antimicrobial proteins of the invention, the α -amylase inhibitor proteins may be useful as fungicides or as antibiotics.

A third antifungal protein has been isolated from radish seeds, hereafter called Rs-nsLTP (Raphanus sativus non-specific lipid transfer protein). It is a dimeric protein, composed of two identical 9 kDa subunits. Amino

acid sequence determination has identified the 43 N-terminal residues of Rs-nsLTP, and has shown it to be homologous with non-specific lipid transfer proteins isolated from other plants (Arondel and Kader, 1990, *Experientia*, 46:579-585) but not with the other antimicrobial proteins discussed above. The Rs-nsLTP sequence enables manufacture of the protein by chemical synthesis using a standard peptide synthesiser.

Knowledge of their primary structure, enables the production of DNA constructs encoding the antimicrobial proteins. The DNA sequence may be predicted from the known amino acid sequence or the sequence may be isolated from plant-derived DNA libraries.

Oligonucleotide probes may be derived from the known amino acid sequence and used to screen a cDNA library for cDNA clones encoding some or all of the protein. cDNA clones encoding the Rs-AFPs have been isolated in this way and sequenced. These same oligonucleotide probes or cDNA clones may be used to isolate the actual AFP, AMP or Rs-nsLTP gene(s) by screening genomic DNA libraries. Such genomic clones may include control sequences operating in the plant genome. Thus it is also possible to isolate promoter sequences which may be used to drive expression of the antimicrobial (or other) proteins. These promoters may be particularly responsive to environmental conditions (such as the presence of a fungal pathogen).

DNA encoding the antimicrobial proteins (which may be a cDNA clone, a genomic DNA clone or DNA manufactured using a standard nucleic acid synthesiser) can then be cloned into a biological

system which allows expression of the proteins. Hence the proteins can be produced in a suitable micro-organism or cultured cell, extracted and isolated for use. Suitable micro-organisms include
5 Escherichia coli and Saccharomyces cerevisiae. The genetic material can also be cloned into a virus or bacteriophage. Suitable cells include cultured insect cells and cultured mammalian cells. The DNA can also be transformed by known methods into any
10 plant species, so that the antimicrobial proteins are expressed within the plant.

Plant cells according to the invention may be transformed with constructs of the invention according to a variety of known methods
15 (Agrobacterium Ti plasmids, electroporation, microinjection, microprojectile gun, etc). The transformed cells may then in suitable cases be regenerated into whole plants in which the new nuclear material is stably incorporated into the
20 genome. Both transformed monocot and dicot plants may be obtained in this way, although the latter are usually more easy to regenerate.

Examples of genetically modified plants which may be produced include field crops, cereals, fruit
25 and vegetables such as: canola, sunflower, tobacco, sugarbeet, cotton, soya, maize, wheat, barley, rice, sorghum, tomatoes, mangoes, peaches, apples, pears, strawberries, bananas, melons, potatoes, carrot, lettuce, cabbage, onion.

30 The AFP, AMP and Rs-nsLTP proteins show a wide range of antifungal activity, including anti-yeast activity, and the AMPs are also active against Gram positive bacteria. The proteins are useful as fungicides or antibiotics. Exposure of a

plant pathogen to an antimicrobial protein may be achieved by application of the protein to plant parts using standard agricultural techniques (eg spraying). The proteins may also be used to combat fungal or bacterial disease by expression within plant bodies.

All the antimicrobial proteins show surprisingly high activity: they inhibit the growth of a variety of plant pathogenic fungi at submicromolar doses. Antifungal activity of the AMPs is only partially dependent on the ionic conditions. The antifungal effect of the AFPs is not affected by K^+ ions at physiological concentrations (50 mM). The antifungal effect of Rs-AFP1, but not Rs-AFP2, is antagonised by Ca^{2+} at physiological concentrations (1 mM). Rs-nsLTP also inhibits growth of a variety of plant pathogenic fungi, but is less potent and more salt sensitive than the AFPs.

The antimicrobial proteins can be isolated and purified from appropriate seeds, synthesised artificially from their known amino acid sequence, or produced within a suitable micro-organism by expression of recombinant DNA. The proteins may also be expressed within a transgenic plant.

The invention may be further understood by reference to the drawings, in which:

Figure 1 shows the cation exchange chromatogram for the Raphanus antifungal proteins and the associated graph of fungal growth inhibition.

Figure 2A shows the HPLC profile of purified Rs-AFP1.

Figure 2B shows the HPLC profile of purified Rs-AFP2 and Rs-nsLTP.

Figure 3 shows native gel electrophoresis and bio-zymography of the purified Rs-AFP1 and Rs-AFP2.

5 Figure 4 shows the cation exchange chromatogram for the B napus antifungal proteins and the associated graph of fungal growth inhibition.

10 Figure 5 shows the HPLC profile of purified B napus antifungal proteins.

Figure 6 shows the cation exchange chromatogram for B rapa antifungal proteins and the associated graph of fungal growth inhibition.

15 Figure 7 shows the HPLC profile of purified B rapa antifungal proteins.

Figure 8 shows the cation exchange chromatogram for S alba antifungal proteins and the associated graph of fungal growth inhibition.

20 Figure 9 shows the HPLC profile of purified S alba antifungal proteins.

Figure 10 shows the cation exchange chromatogram for A thaliana antifungal protein and the associated graph of fungal growth inhibition.

25 Figure 11 shows the HPLC profile of purified A thaliana antifungal proteins.

Figure 12 shows the cation exchange chromatogram for the basic extract of Dahlia merckii and the corresponding graph of antifungal activity.

30 Figure 13 shows the reverse-phase HPLC profile of purified Dm-AMP1 and Dm-AMP2.

Figure 14 shows the cation exchange chromatogram for the basic extract of Cnicus benedictus and the corresponding graph of antifungal activity.

5 Figure 15 shows the reverse-phase HPLC profile of purified Cb-AMP1.

Figure 16 shows the reverse-phase HPLC profile of purified Cb-AMP2.

10 Figure 17 shows the cation exchange chromatogram for the basic extract of Lathyrus and the corresponding graph of antifungal activity.

Figure 18 shows the reverse-phase HPLC profile of purified Lc-AFP.

15 Figure 19 shows the cation exchange chromatogram for the basic extract of Clitoria and the corresponding graph of antifungal activity.

Figure 20 shows the reverse-phase HPLC profile of purified Ct-AMP1.

20 Figure 21 shows the reverse-phase HPLC profile of purified Ct-AMP2.

Figure 22 shows the SDS-PAGE analysis of the purified Rs-AFPs.

Figure 23 shows the SDS-PAGE analysis of the purified Rs-nsLTP.

25 Figure 24 shows the SDS-PAGE analysis of the purified Dm-AMPs.

Figure 25 shows the SDS-PAGE analysis of the purified Cb-AMPs.

30 Figure 26 shows the SDS-PAGE analysis of the purified Lc-AFP and Ct-AMPs.

Figure 27 shows the amino acid sequences of Rs-AFP1, Rs-AFP2 and the related Brassicaceae proteins.

Figure 28 shows the amino acid sequences of the Dm-AMPs and the Cb-AMPs.

Figure 29 shows the amino acid sequences of Lc-AFP and Ct-AMP1.

5 Figure 30 shows the alignment of the amino acid sequences of Rs-AFP1, Dm-AMP1, the Cb-AMPs, Lc-AFP, Ct-AMP1, sorghum SI α 2, wheat γ 1 purothionin, and the predicted products of the pea genes pI230 and pI39, of the cowpea gene pSAS10, and of the potato gene p322.

10 Figure 31A shows predicted DNA sequences for the Dm-AMP and Cb-AMP genes.

Figure 31B shows predicted DNA sequences for the Lc-AFP and Ct-AMP1 genes.

15 Figure 32 shows the amino acid sequence of Rs-nsLTP.

Figure 33 shows the alignment of the amino acid sequences of Rs-nsLTP and various plant non-specific lipid transfer proteins.

20 Figure 34 is a graph of Rs-AFP2 in vivo activity.

Figure 35 shows the full length cDNA sequence of Rs-AFP1.

25 Figure 36 shows the truncated cDNA sequence of Rs-AFP2.

Figure 37 shows the full length DNA sequence of PCR assisted site directed mutagenesis of Rs-AFP2.

30 Figure 38 shows the expression vector pFRG7.

Figure 39 shows the expression vector pFRG8.

The following Examples illustrate the invention.

EXAMPLE 1

Antifungal and antibacterial activity assays.

Antifungal activity was measured by microspectrophotometry as previously described (Broekaert, 1990, FEMS Microbiol Lett, 69:55-60). Routinely, tests were performed with 20 μ l of a (filter-sterilized) test solution and 80 μ l of a suspension of fungal spores (2×10^4 spores/ml) in half strength potato dextrose broth (1/2 PDB). Some tests were performed using a suspension of mycelium fragments in a synthetic growth medium. The synthetic growth medium consisted of K_2HPO_4 (2.5 mM), $MgSO_4$ (50 μ M), $CaCl_2$ (50 μ M), $FeSO_4$ (5 μ M), $CoCl_2$ (0.1 μ M), $CuSO_4$ (0.1 μ M), Na_2MoO_4 (2 μ M), H_3BO_3 (0.5 μ M), KI (0.1 μ M), $ZnSO_4$ (0.5 μ M), $MnSO_4$ (0.1 μ M), glucose (10 g/l), asparagine (1 g/l), methionine (20 mg/l), myo-inositol (2 mg/l), biotin (0.2 mg/l), thiamine-HCl (1 mg/l), and pyridoxine-HCl (0.2 mg/l). Control microcultures contained 20 μ l of sterile distilled water and 80 μ l of the fungal suspension.

Unless otherwise stated the test organism was Fusarium culmorum (strain IMI 180420) and incubation was done at 25°C for 48 hours. Percent growth inhibition is defined as 100 times the ratio of the corrected absorbance of the control microculture minus the corrected absorbance of the test microculture over the corrected absorbance at 595 nm of the control microculture. The corrected absorbance values equal the absorbance at 595 nm of the culture measured after 48 hours minus the absorbance at 595 nm measured after 30 min.

Antibacterial activity was measured microspectrophotometrically as follows. A

bacterial suspension was prepared by inoculating soft nutrient agarose (tryptone, 10 g/l; Seaplaque agarose (FMC), 5 g/l). Aliquots (80 μ l) of the bacterial suspension (10^5 colony forming units per ml) were added to filter-sterilized samples (20 μ l) in flat-bottom 96-well microplates. The absorbance at 595 nm of the culture was measured with the aid of a microplate reader after 30 minutes and 24 hours of incubation at 28°C. Percent growth inhibition was calculated as described above for the antifungal activity assay.

EXAMPLE 2

Extraction of the basic protein fraction from Raphanus sativus seeds.

Ammonium sulphate fractionation of proteins precipitating in the interval of 30 to 70% relative saturation was followed by heat treatment to remove heat-labile proteins, and by isolation of the basic protein fraction ($pI > 9$) by passage over a Q-Sepharose (Pharmacia) anion exchange column equilibrated at pH 9. The detailed methods are described below.

One kg of R sativus seeds (obtained from Aveve, Belgium) was ground in a coffee mill and the resulting meal was extracted for 2 hours at 4°C with 2 litres of an ice-cold extraction buffer containing 10 mM NaH_2PO_4 , 15 mM Na_2HPO_4 , 100 mM KCl, 2 mM EDTA, 2 mM thiourea, and 1 mM PMSF. The homogenate was squeezed through cheesecloth and clarified by centrifugation (30 min at 7,000 x g). Solid ammonium sulphate was added to the supernatant to obtain 30% relative saturation and

the precipitate formed after standing overnight at room temperature was removed by centrifugation (30 min at 7,000 x g). The supernatant was adjusted to 70% relative ammonium sulphate saturation and the precipitate formed overnight at room temperature collected by centrifugation (30 min at 7,000 x g). After redissolving the pellet in 400 ml distilled water the solution was heated at 80°C for 15 min. The coagulated insoluble material was removed by centrifugation (30 min at 7,000 x g) and the supernatant was dialyzed extensively against distilled water using tubing (SpectralPor, Spectrum, USA) with a molecular weight cut off of 1,000 Da. After dialysis the solution was adjusted to 50 mM Tris-HCl (pH 9) by addition of the ten-fold concentrated buffer, and subsequently passed over a Q-Sepharose Fast Flow (Pharmacia, Uppsala, Sweden) column (12 x 5 cm) in equilibrium with 50 mM Tris-HCl (pH 9). The protein fraction passed through the column was dialyzed extensively against distilled water and adjusted to 50 mM sodium N-morpholinoethanesulphonic acid (Na-MES), pH6, by addition of the ten-fold concentrated buffer.

This material represents the basic heat-stable protein fraction of R sativus seeds. Its further chromatographic purification is described in Example 3.

EXAMPLE 3

Purification of antifungal proteins from R sativus seeds.

5 The starting material for the isolation of the R sativus antifungal proteins was the basic heat-stable protein fraction extracted from the mature seeds as in Example 2. These proteins were further separated by cation exchange chromatography, as shown in Figure 1.

10 About 150 mg of the basic heat-stable protein fraction dissolved in 50 mM sodium MES (pH 6) was applied on a S-Sepharose High Performance (Pharmacia) column (10 x 1.6 cm) previously equilibrated with the sodium MES buffer. The
15 column was eluted at 2.5 ml/min with a linear gradient of 1000 ml from 0 to 500 mM NaCl in 50 mM sodium MES buffer (pH 6). The eluate was monitored for protein by online measurement of the absorbance at 280 nm (results shown in the lower panel of
20 Figure 1) and collected in 10 ml fractions. Of these fractions, 20 μ l was tested in the microspectrophotometric antifungal activity assay described in Example 1 using either the synthetic growth medium (Medium A: results shown as full
25 lines in the upper panel of Figure 1) or the same medium supplemented with 1 mM CaCl_2 and 50 mM KCl (Medium B: results shown as dashed lines in the upper panel of Figure 1).

30 Upon fractionation, the mixture yielded a broad peak representing the unbound fraction, two well resolved peaks (peak 1 and peak 2) eluting around 100 and 200 mM NaCl respectively, and a group of five non-resolved peaks (peaks 3 to 7) eluting between 250 and 450 mM NaCl. No antifungal

activity was associated with the unbound fraction, whereas all bound peak fractions displayed antifungal activity when assayed in medium A. However, tests performed in medium B only indicated growth inhibition for the fractions corresponding to peaks 1 and 2, respectively. It appears therefore that the antifungal activity of these fractions is less salt-dependent than that of the fractions from peaks 3 to 7.

The fractions showing antifungal activity in growth medium B (peaks 1 and 2) were further purified by reversed-phase chromatography. About 1 mg amounts of peak 1 material (Figure 2A) and peak 2 material (Figure 2B) were loaded on a Pep-S (porous silica C₂/C₁₈, Pharmacia) column (25 x 0.93 cm) in equilibrium with 0.1% TFA. The column was eluted at 5 ml/min with a linear gradient of 200 ml from 0.1% trifluoroacetic acid (TFA) to 40% acetonitrile/0.1% TFA. The eluate was monitored for protein by online measurement of the absorption at 214 nm. Five ml fractions of the eluate were collected, vacuum-dried, and finally dissolved in 0.5 ml distilled water of which 10 µl was used in a microspectrophotometric antifungal activity assay.

Figure 2A and Figure 2B show the HPLC profiles of purified peak 1 and peak 2 material respectively. The lower panels show monitoring of the eluate for protein by measurement of the absorbance at 214 nm. Results of the microspectrophotometric antifungal activity assay in medium A (full line) and medium B (dashed line) are shown in the upper panels.

The material from peak 1 yielded a single major peak eluting at 30% acetonitrile and

co-eluting with the antifungal activity in both medium A and medium B. The active factor isolated from this peak is called Rs-AFP1 (Raphanus sativus antifungal protein 1). The peak 2 material, on the other hand, resolved into two major peaks eluting at 30% and 33% acetonitrile respectively. The peak eluting at 30% acetonitrile was active in both medium A and medium B, whereas the peak eluting at 33% was active only in medium A. The active factor purified from the 30% acetonitrile peak is called Rs-AFP2 (Raphanus sativus antifungal protein 2), and that from the 33% acetonitrile peak is designated Rs-nsLTP (Raphanus sativus non-specific lipid transfer protein) because of its homology with non-specific lipid transfer proteins isolated from other plant species (see Example 13).

EXAMPLE 4

Purity of the isolated Rs-AFPs.

The purity of the isolated antifungal proteins was verified by native cathodic gel electrophoresis followed by protein staining (Figure 3, left panel) and in situ detection of antifungal activity using a bio-zymographic technique (Figure 3, right panel).

Native cathodic gel electrophoresis and bio-zymography were done as previously described (De Bolle et al, 1991, Electrophoresis, 12, 442-444) with some modifications. Electrophoresis was performed on continuous 10% acrylamide gels containing 60 mM Tris/70 mM MES (pH 7). The electrophoresis buffer consisted of 100 mM L-histidine/41 mM MES (pH 6.5). Gels were cooled at

10°C during electrophoresis. The samples contained 20% glycerol, 0.0025% methylene blue, and 10 µg of purified Rs-AFP1 or 20 µg of Rs-AFP2. Proteins were detected by silver-staining of a diffusion blot prepared from the gel (Kovarik et al, 1987, Folia Biologica, 33, 253-257). The gel was overlaid with a soft agar gel (De Bolle et al, 1991, Electrophoresis, 12, 442-444) containing viable Trichoderma hamatum spores and incubated at 25°C for 3 days.

Figure 3 (left panel) shows that Rs-AFP1 (lanes 1) and Rs-AFP2 (lanes 2) migrate as single protein bands after cathodic gel electrophoresis. Moreover, the antifungal activity co-migrated exactly with the protein bands in the gel (right panel). These results indicate that the isolated factors are highly pure and that the antifungal activity is not attributable to minor contaminants.

20

EXAMPLE 5

Antifungal proteins related to Rs-AFPs from other species of Brassicaceae.

Using the purification procedure described in Example 3, we have isolated antifungal proteins from other Brassicaceae, including Brassica napus, Brassica rapa, Sinapis alba and Arabidopsis thaliana.

Figure 4 shows the cation exchange chromatogram for antifungal protein isolated from B napus, and the associated graph of fungal growth inhibition (upper panel). Figure 5 shows the HPLC profile of the purified B napus antifungal proteins, isolated from peak 1 (Bn-AFP1, left

panel) and peak 2 (Bn-AFP2, right panel).

Figure 6 shows the cation exchange chromatogram for antifungal protein isolated from B rapa, and the associated graph of fungal growth inhibition (upper panel). Figure 7 shows the HPLC profile of the purified B rapa antifungal proteins, isolated from peak 1 (Br-AFP1, left panel) and peak 2 (Br-AFP2, right panel).

Figure 8 shows the cation exchange chromatogram for antifungal protein isolated from S alba, and the associated graph of fungal growth inhibition (upper panel). Figure 9 shows the HPLC profile of the purified S alba antifungal proteins, isolated from peak 1 (Sa-AFP1, left panel) and peak 2 (Sa-AFP2, right panel).

Figure 10 shows the cation exchange chromatogram for antifungal protein isolated from A thaliana, and the associated graph of fungal growth inhibition (upper panel). Figure 11 shows the HPLC profile of the purified A thaliana antifungal proteins, isolated from peak 1 (At-AFP1).

All these antifungal proteins behave similarly to Rs-AFP1 and Rs-AFP2 with respect to their SDS-PAGE and isoelectric focusing pattern (as described in Example 5).

EXAMPLE 6

Extraction of the basic protein fraction from Dahlia merckii, Cnicus benedictus, Lathyrus cicera and Clitoria ternatea seeds.

Five hundred grams of D merckii or C benedictus or Clitoria ternatea seeds (purchased from Chiltern Seeds, Cumbria, UK) or Lathyrus

cicera seeds (from Instituto Botanico Universidade Coimbra, Portugal) were ground in a coffee mill and the resulting meal was extracted for 2 hours at 4°C with 2 litres of an ice-cold extraction buffer containing 10 mM NaH_2PO_4 , 15 mM Na_2HPO_4 , 100 mM KCl, 2 mM EDTA and 1 mM benzamidine. The resulting homogenate was squeezed through cheesecloth and clarified by centrifugation (30 min at 7,000 x g). Solid ammonium sulphate was added to the supernatant to obtain 75% relative saturation and the precipitate allowed to form by standing overnight at 4°C. Following centrifugation at 7,000 x g for 30 minutes, the precipitate was redissolved in a minimal volume of distilled water and dialyzed extensively against distilled water using benzoylated cellulose tubing (Sigma, St Louis, MO). After dialysis the solution was adjusted to 50 mM NH_4Ac (pH 9) by addition of the ten-fold concentrated buffer and passed over a Q-Sepharose Fast Flow (Pharmacia, Uppsala, Sweden) column (12 x 5 cm) equilibrated in 50 mM NH_4Ac (pH 9). The protein fraction which passed through the column was adjusted to pH6 with acetic acid.

This material represents the basic (pI>9) protein fraction of the seeds. The fractions were further purified as described in Examples 7, 8, 9 and 10.

EXAMPLE 7

Purification of antimicrobial proteins from
Dahlia merckii seeds.

5 The starting material for the isolation of the
D merckii antimicrobial proteins was the basic
protein fraction extracted from the mature seeds as
in Example 6. Proteins were further purified by
cation exchange chromatography of this extract.

10 Approximately 500 ml of the basic protein
fraction was applied to a S-Sepharose High
Performance (Pharmacia) column (10 x 1.6 cm)
equilibrated in 50 mM NH₄Ac, pH 6.0. The column
was eluted at 3.0 ml/min with a linear gradient of
50-750 ml NH₄Ac, pH 6.0 over 325 minutes. The
15 eluate was monitored for protein by online
measurement of the absorbance at 280 nm (results
shown in the lower panel of Figure 12) and
collected in 10 ml fractions. Samples from each
fraction were assayed for antifungal activity as
20 described in Example 1 (results shown in the upper
panel of Figure 12).

Following chromatography, the extract yielded
a broad peak of activity eluting at around 250 mM
NH₄Ac. The fractions showing antifungal activity
25 were pooled and further purified by reverse-phase
HPLC. About 3 mg amounts of the peak were loaded
on a PEP-S (porous silica C₂/C₁₈, Pharmacia) column
(25 x 0.4 cm) equilibrated with 0.1% TFA
(trifluoroacetic acid). The column was developed at
30 1 ml/min with a linear gradient of 0.1% TFA to 100%
acetonitrile/0.1% TFA over 100 minutes. The eluate
was monitored for protein by online measurement of
the absorption at 280 nm (results shown in the
lower panel of Figure 13). One ml fractions were

collected, vacuum-dried, and dissolved in 0.5 ml distilled water. 10 μ l from each fraction was assayed for antifungal activity (results shown in the upper panel of Figure 13). The material yielded two well-resolved peaks of activity, eluting at 18% and 22% acetonitrile. These represent the purified proteins Dm-AMP1 and Dm-AMP2 respectively.

10

EXAMPLE 8

Purification of antimicrobial proteins from Cnicus benedictus seeds.

15

The procedure described in Example 7 was followed using the basic extract from Cnicus benedictus seeds. Following chromatography on the S-Sepharose High Performance column, the Cnicus extract yielded two peaks of antifungal activity eluting at approximately 250 mM (peak 1) and 500 mM (peak 2) NH_4Ac (results shown in Figure 14).

20

Active fractions were pooled for each peak and further purified on reverse-phase HPLC as described in Example 7. Results for peak 1 are shown in Figure 15: it yielded an active factor eluting at 18% acetonitrile which is designated Cb-

25

MP1. Similarly peak 2 eluted to a single peak of activity which is designated Cb-AMP2 (results shown in Figure 16).

EXAMPLE 9

Purification of antifungal protein from
Lathyrus cicera seeds.

5 The procedure described in Example 7 was
followed using the basic extract from Lathyrus
cicera seeds. Following chromatography on the
S-Sepharose High Performance column, the Lathyrus
extract yielded a single peak of antifungal
activity eluting at approximately 160 mM NH₄Ac
10 (results shown in Figure 17).

Active fractions were pooled and further
purified on reverse-phase HPLC as described in
Example 7. Results for peak 1 are shown in Figure
18: it yielded an active factor eluting at 22%
15 acetonitrile which is designated Lc-AFP.

EXAMPLE 10

20 Purification of antimicrobial proteins from
Clitoria ternatea seeds.

The procedure described in Example 7 was
followed using the basic extract from Clitoria
ternatea seeds. Following chromatography on the
S-Sepharose High Performance column, the Clitoria
25 extract yielded two partially resolved peaks of
antifungal activity eluting between 260 mM and 400
mM NH₄Ac (results shown in Figure 19).

Active fractions were pooled for each peak and
further purified on reverse-phase HPLC as described
30 in Example 7. Results for peak 1 are shown in
Figure 20: it yielded an active factor eluting at
approximately 18% acetonitrile which is designated
Ct-AMP1. Similarly peak 2 yielded an active factor
eluting at approximately 18% acetonitrile which is

designated Ct-AMP2 (results shown in Figure 21).

EXAMPLE 11

5 Molecular structure of the purified antimicrobial proteins.

6 The molecular structure of the purified
7 antimicrobial proteins was further analysed.
8 Sodium dodecyl sulphate polyacrylamide gel
9 electrophoresis (SDS-PAGE) was performed on precast
10 commercial gels (PhastGel High Density from
11 Pharmacia) using a PhastSystem (Pharmacia)
12 electrophoresis apparatus. The sample buffer
13 contained 200 mM Tris-HCl (pH 8.3), 1% (w/v) SDS, 1
14 mM EDTA, 0.005% bromophenol blue and, unless
15 otherwise stated, 1% (w/v) dithioerythritol (DTE).
16 Proteins were fixed after electrophoresis in 12.5%
17 glutaraldehyde and silver-stained according to
18 Heukeshoven and Dernick (1985, Electrophoresis, 6,
19 103-112).
20

21 The Rs-AFPs were analysed by SDS-PAGE. After
22 reduction with β -mercaptoethanol and modification
23 of the cysteine residues by S-pyridylethylation,
24 both Rs-AFP1 and Rs-AFP2 show single bands with an
25 apparent molecular mass of about 5 kDa. After
26 simple reduction without further cysteine
27 derivatisation, the 5 kDa band is always
28 accompanied by a 16 kDa band at variable yields,
29 which may represent an oligomeric form of the 5 kDa
30 protein resisted during electrophoresis. Unreduced
31 Rs-AFP1 and Rs-AFP2 migrate as single bands of 20
32 kDa and 17 kDa, respectively. These results show
33 that the native Rs-AFPs are oligomeric proteins,
34 consisting of dimers, trimers or tetramers of the 5

kDa polypeptide. The oligomeric structure appears to be stabilised by disulphide linkages.

Figure 22 shows the SDS-PAGE analysis of the purified Rs-AFPs: lane 1 is unreduced Rs-AFP1,
5 lane 2 is reduced and S-pyridylethylated Rs-AFP1,
lane 3 is unreduced Rs-AFP2,
lane 4 is reduced and S-pyridylethylated Rs-AFP2.
Two hundred nanograms of the proteins were separated on the gels. Lane M shows myoglobin
10 fragments used as molecular weight markers (Pharmacia) with the following sizes:
17 kDa, 14.5 kDa, 8 kDa, 6 kDa, and 2.5 kDa.

SDS-PAGE analysis of Rs-nsLTP after reduction with DTE yielded a single 9 kDa band. The
15 unreduced Rs-nsLTP migrated as a single 18 kDa band. It appears therefore that Rs-nsLTP is a dimeric protein (2 x 9 kDa) stabilised by disulphide bridges.

Figure 23 shows the SDS-PAGE analysis of the purified Rs-nsLTP: Lane 1 is unreduced Rs-nsLTP,
20 lane 2 is reduced Rs-nsLTP. Molecular weight markers (lane M) are as in Figure 22.

Free cysteine thiol groups of the Rs-AFPs were assessed qualitatively as follows. Hundred μ g
25 amounts of reduced or unreduced proteins were dissolved in 6 M guanidinium-Cl containing 100 mM sodium phosphate buffer (pH 7) and 1 mM EDTA. The mixtures were allowed to react with
30 5,5'-dithionitrobenzoic acid and monitored for release of nitrothiobenzoate as described by Creighton (1989, Protein structure, a practical approach, 155-167). Reduction of the proteins was done by addition of Tris-HCl (pH 8.6) to 100 mM and dithioerythritol to 30 mM, followed by incubation

at 45°C for 1 hour. The proteins were separated from the excess reagents by reversed-phase chromatography on a C₂/C₁₈ silica column.

5 The unreduced Rs-AFPs did not contain free cysteine thiol groups, whereas the reduced proteins did, indicating that all cysteine residues participate in disulphide bonds.

10 The pI values of Rs-AFP1 and Rs-AFP2 were determined by isoelectric focusing and found to be higher than 10 for both proteins. Isoelectric focusing was performed on precast Immobiline Dry Strips (Pharmacia) rehydrated in 8 M urea, using marker proteins in the pI range from 4.7 to 10.6 (Pharmacia).

15 Figure 24 shows the SDS-PAGE analysis of the two purified proteins from Dahlia; Figure 25 shows the SDS-PAGE analysis of the two purified Cnicus proteins. Molecular weight markers were run as reference proteins (lane M: 29 kDa, 20.1 kDa, 13.2 kDa and 5.2 kDa). When reduced with DTT, all four
20 proteins run as 5/6 kDa bands (Figure 24, lanes 2 and 4; Figure 25, lanes 2 and 4). In their unreduced form, the purified proteins run as oligomers. Unreduced Dm-AMP1 runs as a 24 kDa
25 protein (Figure 24, lane 1) and Dm-AMP2 as a 17 kDa protein (Figure 24, lane 3). Similarly, unreduced Cb-AMP1 runs as a single band of 30 kDa (Figure 25, lane 1) and Cb-AMP2 as a band of 18 kDa (Figure 25, lane 3).

30 Figure 26 shows the SDS-PAGE analysis of the two purified proteins from Clitoria and the purified proteins from Lathyrus. Molecular weight markers were run as reference proteins (lane M: 29 kDa, 20.1 kDa, 13.2 kDa and 5.2 kDa). When reduced

with DTT, all three proteins run as 5/6 kDa bands (Figure 26: lane 2, Ct-AMP1; lane 4, Ct-AMP2; lane 6, Lc-AFP). In their unreduced form, the purified proteins run as oligomers. Unreduced Ct-AMP1 and Ct-AMP2 run as proteins of approximately 15 kDa (Figure 26, lanes 1 and 3 respectively) whereas unreduced Lc-AFP runs as an approximately 12 kDa protein (Figure 26, lane 5).

EXAMPLE 12

Amino acid sequencing of the Rs-AFPs and related proteins.

Cysteine residues of the antifungal proteins were modified by S-pyridylethylation using the method of Fullmer (1984, Anal Biochem, 142, 336-341). Reagents were removed by HPLC on a Pep-S (porous silica C₂/C₁₈) (Pharmacia) column (25 x 0.4 cm). The S-pyridylethylated proteins were recovered by eluting the column with a linear gradient from 0.1 % trifluoroacetic acid (TFA) to acetonitrile containing 0.1 % TFA. The resulting protein fractions were subjected to amino acid sequence analysis in a 477A Protein Sequencer (Applied Biosystems) with on-line detection of phenylthiohydantoin amino acid derivatives in a 120A Analyser (Applied Biosystems). Where necessary due to the proteins being blocked, treatment of the S-pyridylethylated proteins with pyroglutamate amino peptidase was done according to the supplier's instructions (Boehringer Mannheim, Mannheim, FRG).

The N-terminal amino acid sequence of Rs-AFP1 and Rs-AFP2 was determined by automated Edman

degradation, after treatment with pyroglutamate amino peptidase which cleaves off cyclic N-terminal glutamate residues. Figure 27 shows the sequence of the first 44 N-terminal amino acids of Rs-AFP1 and of the first 35 residues of Rs-AFP2. The sequences of Rs-AFP1 and Rs-AFP2 differ at only two positions within the first 36 residues. The replacement of a glutamic acid by a glutamine (position 4) and an asparagine by an arginine (position 27) in Rs-AFP2 are consistent with the higher net positive charge of this protein relative to Rs-AFP1, which was previously evidenced by cathodic gel electrophoresis (Figure 3) and cation exchange chromatography (Figure 1). Rs-AFP1 appears to be rich in cysteine and basic amino acids (5 and 9 respectively within the first 45 residues). The molecular mass of Rs-AFP1 calculated on the basis of the partial amino acid sequence (4964 Da) is very close to the value estimated by SDS-PAGE (about 5000 Da) which indicates that the determined sequence encompasses the major part of the protein. However, it is anticipated that Rs-AFP1 contains at least one more cysteine, since the absence of free thiol groups assumes an even number of cysteines.

Figure 27 also shows the first 23 to 30 N-terminal amino acids of the Rs-AFP-like proteins isolated from other Brassicaceae as described in Example 5 (Bn-AFP1, Bn-AFP2, Br-AFP1, Br-AFP2, Sa-AFP1, Sa-AFP2, At-AFP1). All proteins were treated with pyroglutamate amino peptidase prior to sequencing but the cysteine residues were not modified. Consequently, cysteine residues appear as blanks upon Edman degradation. Amino acids

identical to the corresponding amino acids in Rs-AFP1 are shown by dots. It appears therefore that the Rs-AFP-like proteins from other members of the family Brassicaceae are identical or nearly identical to Rs-AFP1 and Rs-AFP2. Br-AFP2 contains an unidentified uncommon amino acid at position 11.

Figure 28 shows the complete amino acid sequence for the peptides Dm-AMP1, Cb-AMP1 and Cb-AMP2. Shown also is the sequence for the first 20 N-terminal amino acids of Dm-AMP2. The sequences for Dm-AMP1 and Dm-AMP2 differ at only one position (position 2) in these first 20 amino acids. Comparing the sequences for Cb-AMP1 and Cb-AMP2, there are three changes. The substitution of an acidic residue (aspartic acid at position 22) in Cb-AMP1 for a neutral asparagine in Cb-AMP2 and the substitution of glutamine at position 23 for a basic lysine are consistent with the higher net positive charge. Similarly, Cb-AMP2 also differs from Dm-AMP1 at two positions although the result is the net gain of two positive charges.

All four proteins show striking similarity to the proteins isolated from seeds of the Brassicaceae family. Alignment of the amino acid sequence for Rs-AFP1 (Raphanus Sativus - Antifungal Protein 1) with the sequence for Dm-AMP1 reveals that they have approximately 50% identical residues.

Figure 29 shows the complete amino acid sequence for the peptides Lc-AFP and Ct-AMP1. Ct-AMP2 is expected to be highly homologous to Ct-AMP1. Both Lc-AFP and Ct-AMP1 are also homologous to the Compositae and Brassicaceae proteins. In particular Ct-AMP1 is very homologous

to the Dahlia peptide Dm-AMP1, having 35 identical residues in its sequence.

Homologies can be found between this group of closely related proteins and the products encoded by two pea (Pisum sativum) genes, pI39 and pI230, which are specifically induced by the fungus Fusarium solani (Chiang and Hadwiger, 1991, Mol Plant Microbe Interact, 4, 324-331), and with the protein product of potato (Solanum tuberosum) gene p322 (Stiekema et al, 1988, Plant Mol Biol, 11, 255-269). Nothing is known about the biological properties of the proteins encoded by genes pI39, pI230 or p322. In addition, the Rs-AFP-like/Dahlia/Cnicus/Lathyrus/Clitoria class of antimicrobial proteins show homology to inhibitors of insect gut α -amylases from Sorghum bicolor (Bloch and Richardson, 1991, FEBS Lett, 279, 101-104), and also to γ -purothionins from Triticum aestivum (Colilla et al, 1990, FEBS Lett, 270, 191-194) which inhibit in vitro protein synthesis in cell-free systems (Mendez et al, 1990, Eur J Biochem, 194, 533-539).

Figure 30 shows the alignment of the amino acid sequences of Rs-AFP1, Dm-AMP1, the Cb-AMPs, Lc-AFP, Ct-AMP1, the sorghum α -amylase inhibitor SI α 2, wheat γ 1 purothionin, and the predicted sequences of the mature protein products of the Fusarium-induced pea genes pI230 and pI39, of the cowpea gene pSAS10, and of the potato gene p322. Sequence identities and conserved changes compared with Rs-AFP1 are boxed. Conserved changes are considered as substitutions within the amino acid homology groups FWY, MILV, RHK, EDNQ, and PAGST. Gaps introduced for optimal alignment are

represented by dashes.

Upon alignment of the sequences, all of the cysteines and most of the glycines appear at conserved positions, suggesting their importance with respect to structure and function of these proteins. Also noteworthy are the conserved aromatic residues at positions 11 and 40.

Figure 31A shows one of the possible DNA sequences of the genes encoding Dm-AMP1, Dm-AMP2, Cb-AMP1 and Cb-AMP2. Similarly Figure 31B shows one of the possible DNA sequences of the genes encoding Lc-AFP and Ct-AMP1. These gene sequences have been predicted from the known amino acid sequences using codons which commonly occur in dicotyledonous plants. The actual gene sequences within the seed may differ due to the degeneracy of the genetic code.

20

EXAMPLE 13

Amino acid sequencing of Rs-nsLTP.

Amino acid sequencing of the Rs-nsLTP protein was carried out according to the description in Example 12.

25

Figure 32 shows the first 43 N-terminal amino acids of Rs-nsLTP of which the cysteine residues were modified by S-pyridylethylation. In Figure 33 the sequence of Rs-nsLTP is aligned with the N-terminal sequences of non-specific lipid transfer proteins isolated from Spinacia oleracea (So-nsLTP; Bernhard et al, 1990, Plant Physiol, 95, 164-170), Ricinus communis (Rc-nsLTP; Takishima et al, 1986, Biochim Biophys Acta, 870, 248-255), Daucus carota (Dc-nsLTP; Stenk et al, 1991, Plant Cell, 9,

30

907-921), Hordeum vulgare (Hv-nsLTP; Bernhard and Somerville, 1989, Arch Biochem Biophys, 269, 695-697), and Zea mays (Zm-nsLTP; Tchang et al, 1988, J Biol Chem, 263, 16849-16855). Gaps
5 introduced for optimal alignment of the sequences are indicated by dashes. Identical amino acids and conserved substitutions occurring in at least 4 of the 6 sequences are boxed. Conserved changes are
10 considered as substitutions within the amino acid homology groups FWY, MILV, RHK, EDNQ and PAGST. Rs-nsLTP shows 38 to 53% sequence identity with the non-specific lipid transport proteins from other plant sources. Non-specific lipid transport
15 proteins are proteins that can translocate phospholipids or other apolar compounds between two membrane systems. These proteins were previously thought to play a role in the transport of phospholipids from endoplasmic reticulum to cell and organelle membranes (Arondel and Kaden, 1990,
20 Experientia, 46, 579-585). However, recent evidence shows that nsLTPs are located extra-cellularly, making their proposed function in membrane biogenesis unlikely (Sterk et al, 1991, Plant Cell, 3, 907-921).

25

EXAMPLE 14

Stability of the proteins' antifungal activity.

30 Tests for antifungal activity were performed with 20 μ l samples diluted five-fold with growth medium containing Fusarium culmorum spores, according to the assay method given in Example 1. Untreated control samples consisted of the test

proteins at 500 $\mu\text{g}/\text{ml}$ in 10 mM sodium phosphate buffer (pH 7). Heat stability tests were performed by heating aliquots of the test proteins for 10 minutes at different temperatures up to 100°C.

5 Reduction of disulphide bridges was done by addition of dithiothreitol at 30 mM and Tris-HCl (pH 8.6) at 300 mM. The reagents were removed by reversed-phase chromatography. For digestions, different proteases were added at 100 $\mu\text{g}/\text{ml}$ and
10 incubated at 37°C for 16 hours. The control treatment containing only the reagents proved negative for antifungal activity after the reversed-phase chromatography step.

The antifungal activity of all the purified
15 proteins tested was resistant to heat treatments at up to 100°C for 10 minutes. Reduction of their disulphide bonds by dithiothreitol, however, completely abolished the antifungal activity. These disulphide linkages are essential for
20 biological activity. Treatment of the Rs-AFP proteins with trypsin, chymotrypsin, proteinase K or pronase E reduced the antifungal activity by at least 10-fold.

25

EXAMPLE 15

Antifungal potency of the proteins.

The antifungal potency of the purified
proteins was assessed on different plant pathogenic
30 fungi, using the assay described in Example 1. Growth of fungi, collection and harvest of fungal spores, and preparation of mycelial fragments were done as previously described (Broekaert et al, 1990, FEMS Microbiol Lett, 69:55-60). The

following fungal strains were used: Alternaria
brassicola MUCL 20297, Ascochyta pisi MUCL 30164,
Botrytis cinerea MUCL 30158, Cercospora beticola
strain K897, Cladosporium sphaerosperum (K0791),
5 Colletotrichum lindemuthianum MUCL 9577, Fusarium
culmorum IMI 180420, Fusarium oxysporum f.sp. pisi
IMI 236441, Fusarium oxysporum f.sp. lycopersici
MUCL 909, Mycosphaerella fijiensis var fijiensis
IMI 105378, Nectria haematococca Collection Van
10 Etten 160-2-2, Penicillium digitatum (K0879), Phoma
betae MUCL 9916, Pyrenophora tritici-repentis MUCL
30217, Pyricularia oryzae MUCL 30166, Rhizoctonia
solani CBS 207-84, Sclerotinia sclerotianum MUCL
30163, Septoria nodorum MUCL 30111, Septoria
15 tritici (K1097D), Trichoderma hamatum MUCL 29736,
Trichoderma viride (K1127), Verticillium
albo-atrum (K0937), Verticillium dahliae MUCL
19210, Venturia inaequalis MUCL 15927.

For C beticola, R solani, S sclerotianum, S
20 nodorum and M fijiensis, mycelial fragments were
used as inoculum, whereas all other fungi were
inoculated as spores.

Serial dilutions of the antifungal proteins
were applied to the fungi, either using growth
25 medium A or medium B. The percent growth
inhibition was measured by microspectrophotometry.
The concentration required for 50% growth
inhibition after 48 h of incubation (IC_{50} value)
was calculated from the dose-reponse curves. The
30 IC_{50} values for the slow growing fungi S nodorum
and V inaequalis was measured after 5 and 15 days
of incubation respectively.

The results for Rs-AFP1 and Rs-AFP2 are
summarised in Table 1.

TABLE 1
ANTIFUNGAL ACTIVITY OF RS-AFP1 AND RS-AFP2

| Fungus | IC ₅₀ (μg/ml) | | | |
|---------------------------|--------------------------|---------|----------|---------|
| | Medium A | | Medium B | |
| | RS-AFP1 | RS-AFP2 | RS-AFP1 | RS-AFP2 |
| <u>A brassicola</u> | 15 | 2 | >100 | 20 |
| <u>A pisi</u> | 5 | 4 | >100 | 50 |
| <u>B cinerea</u> | 8 | 2 | >100 | >100 |
| <u>C beticola</u> | 2 | 2 | 100 | 3 |
| <u>C lindemuthianum</u> | 100 | 3 | >100 | >100 |
| <u>F culmorum</u> | 12 | 2 | 70 | 5 |
| <u>F oxysporum pisi</u> | 30 | 2 | >100 | >100 |
| <u>F oxysporum</u> | | | | |
| <u>lycopersici</u> | 15 | 2 | >100 | >100 |
| <u>M fijiensis</u> | 4 | 1.5 | 30 | 10 |
| <u>N haematococca</u> | 6 | 2 | >100 | 30 |
| <u>P betae</u> | 2 | 1 | 20 | 6 |
| <u>P tritici-repentis</u> | 3 | 1.5 | 30 | 7 |
| <u>P oryzae</u> | 0.3 | 0.4 | >100 | 7 |
| <u>R solani</u> | 100 | >100 | >100 | >100 |
| <u>S sclerotianum</u> | 20 | >100 | >100 | >100 |
| <u>S nodorum</u> | 20 | 15 | 100 | 20 |
| <u>T hamatum</u> | 2 | 2 | 20 | 4 |
| <u>V dahliae</u> | 5 | 1.5 | >100 | 50 |
| <u>V inaequalis</u> | ND | 25 | ND | >50 |

ND = not determined

The concentration of Rs-AFPs required for 50% growth inhibition in medium A varied from 0.3 $\mu\text{g/ml}$ to over 100 $\mu\text{g/ml}$, depending on the test organism. The antifungal potency of Rs-AFP1 is generally slightly lower than that of Rs-AFP2 in medium A. The difference in antifungal potency between Rs-AFP1 and Rs-AFP2 is more pronounced for the tests performed in medium B. Rs-AFP1 only inhibits 4 out of 17 fungi by more than 50% at concentrations below 100 $\mu\text{g/ml}$, whereas Rs-AFP2 is inhibitory on 11 out of 18 fungi at this concentration. For some fungi, such as F culmorum and C beticola, the IC_{50} value of Rs-AFP2 measured in medium A is comparable to that obtained in medium B. On other fungi, such as F oxysporum f.sp. pisi, the IC_{50} value of Rs-AFP2 is increased from 2 $\mu\text{g/ml}$ in medium A to over 100 $\mu\text{g/ml}$ in medium B.

The antifungal potency of the Rs-AFP-like proteins from B napus, B rapa, S alba and A thaliana was compared to that of Rs-AFP1 and Rs-AFP2 using five different test fungi. The results of these experiments are shown in Table 2. With the exception of Br-AFP2, all proteins had specific activities comparable to that of the Rs-AFPs. The fact that Br-AFP2 is on average 20-fold less active than the related species may be related to the observation that Br-AFP2 has an uncommon amino acid at position 11 (see Figure 27) whereas the Rs-AFPs and related proteins all have an aromatic residue at this position (see Figure 30). When tested in medium B, Rs-AFP2 appears to be the most potent protein, especially on the fungus F culmorum.

TABLE 2

Antifungal Activity of Rs-AFP-like proteins from Brassica rapa, Brassica napus,
Sinapis alba and Arabidopsis thaliana

IC₅₀ (μg/ml) in medium A

| Fungus | Rs-AFP1 | Rs-AFP2 | Br-AFP1 | Br-AFP2 | Bn-AFP1 | Bn-AFP2 | Sa-AFP1 | Sa-AFP2 | At-AFP1 |
|-----------------------|---------|---------|---------|---------|---------|---------|---------|---------|---------|
| <i>A brassicicola</i> | 15 | 2 | 3 | 75 | 0.60 | 1.20 | 1.2 | 4.5 | 10 |
| <i>B cinerea</i> | 8 | 2 | 1.50 | >100 | 2 | 2 | 1.8 | 3.5 | 3.90 |
| <i>F culmorum</i> | 12 | 2 | 2 | 38 | 2.80 | 2.10 | 4 | 2.3 | 3 |
| <i>F oxysporum</i> | 15 | 2 | 1.80 | 42 | 1.30 | 1.50 | 6 | 2.3 | 3 |
| <i>lycopersici</i> | | | | | | | | | |
| <i>P oryzae</i> | 0.3 | 0.4 | 0.25 | 3 | 0.35 | 0.25 | 0.5 | 0.3 | 0.25 |
| <i>V dahliae</i> | 5 | 1.5 | 0.80 | 15 | 1.20 | 1 | 1.5 | 1.2 | 1.50 |

IC₅₀ (μg/ml) in medium B

[illegible]

The antifungal potency of Rs-nsLTP is shown in Table 3. On most fungi Rs-nsLTP is 10 to 20 fold less potent relative to Rs-AFP2. Rs-nsLTP also appears to be highly salt-sensitive. None of the 13 fungi tested are inhibited by Rs-nsLTP in Medium B at concentrations below 100 μ g/ml.

TABLE 3
Antifungal Activity of Rs-nsLTP
IC₅₀ (μ g/ml)

| Fungus | Medium A | Medium B |
|-------------------------|----------|----------|
| A <u>brassicola</u> | 48 | 500 |
| A <u>pisi</u> | 41 | 700 |
| B <u>cinerea</u> | 45 | 680 |
| C <u>lindemuthianum</u> | 25 | >1000 |
| F <u>culmorum</u> | 20 | 520 |
| F <u>oxysporum</u> | 54 | >1000 |
| <u>lycopersici</u> | | |
| F <u>oxysporum pisi</u> | 58 | 900 |
| M <u>fijiensis</u> | >100 | >100 |
| N <u>haematococca</u> | 100 | >1000 |
| P <u>betae</u> | 18 | 750 |
| P <u>oryzae</u> | 10 | >1000 |
| T <u>hamatum</u> | 30 | >1000 |
| V <u>dahliae</u> | 7 | 135 |

The results for the Compositae proteins are summarised in Table 4.

5 The concentration of antimicrobial proteins required for 50% growth inhibition in medium A varied from 0.3 $\mu\text{g/ml}$ to over 100 $\mu\text{g/ml}$, depending on the test organism. In general, the antifungal potency of the proteins was in the order: Cb-AMP2 > Cb-AMP1 > Dm-AMP1 > Dm-AMP2. The differences in activity between the proteins is more pronounced in
10 medium B, with Cb-AMP2 showing the best salt tolerance. Dm-AMP1 and Dm-AMP2 only inhibit the growth of 6 out of 11 fungi by more than 50% at concentrations below 100 $\mu\text{g/ml}$, whereas the two Cnicus proteins inhibit the growth of 7 out of 8
15 fungi when assayed in medium B.

Table 5 summarises the results for the antimicrobial proteins isolated from Leguminosae seeds.

20 These proteins are active, although their activity is somewhat lower than that of the Rs-AFPs and Compositae proteins, especially when assayed in high salt buffer, Medium B. In particular, the activity of Lc-AFP is markedly lower and comparable to the activity of Br-AFP2. The amino acid
25 sequence of Lc-AFP also shows a substitution at position 11 which is normally tryptophan (Figures 27 and 29).

30 The high levels of antifungal activities demonstrated in vitro by each of the purified proteins suggest that they may play a role in the defence of seeds or seedlings against fungal attack.

TABLE 4
ANTIFUNGAL ACTIVITY OF THE Dm-AMPS AND THE Cb-AMPS

| FUNGUS | IC ₅₀ (μg/ml) | | | | | | | |
|-------------------------|--------------------------|---------|---------|---------|----------|---------|---------|---------|
| | Medium A | | | | Medium B | | | |
| | Dm-AMP1 | Dm-AMP2 | Cb-AMP1 | Cb-AMP2 | Dm-AMP1 | Dm-AMP2 | Cb-AMP1 | Cb-AMP2 |
| <u>A brassicola</u> | 1.1 | 2 | ND | ND | 140 | 140 | ND | ND |
| <u>B cinerea</u> | 12 | 10 | 5 | 7 | >200 | >200 | 40 | 40 |
| <u>C beticola</u> | 1 | 3 | 1.2 | 1 | 6 | 6 | 5 | 5 |
| <u>C sphaerospermum</u> | 3 | 3 | 1 | 0.35 | 12 | 12 | 8 | 8 |
| <u>F culmorum</u> | 5 | 3 | 5 | 2 | 8 | 55 | 16 | 16 |
| <u>F oxysporum pisi</u> | 2.7 | 17 | ND | ND | >200 | >200 | ND | ND |
| <u>P digitatum</u> | 2 | 2 | 2 | 1.4 | 70 | 50 | 15 | 15 |
| <u>P oryzae</u> | 5 | 6 | ND | ND | >200 | >200 | ND | ND |
| <u>S tritici</u> | 1 | 0.5 | 0.8 | 0.5 | 4 | 2 | 2 | 2 |
| <u>T viride</u> | >80 | >80 | >100 | 40 | >100 | >100 | >100 | >100 |
| <u>V albo-atrum</u> | 4 | 2 | ND | ND | ND | ND | ND | ND |
| <u>V dahliae</u> | 0.3 | 0.6 | 0.5 | 1.2 | 3 | 4 | 5 | 5 |

ND = not determined

TABLE 5
ANTIFUNGAL ACTIVITY of the Ct-AMPs and Lc-AFP

| FUNGUS | IC ₅₀ (μ g/ml) | | | | | |
|-------------------------|--------------------------------|---------|--------|----------|---------|--------|
| | Medium A | | | Medium B | | |
| | Ct-AMP1 | Ct-AMP2 | Lc-AFP | Ct-AMP1 | Ct-AMP2 | Lc-AFP |
| <u>B cinerea</u> | 37 | 15 | 80 | >150 | >150 | >200 |
| <u>C sphaerospermum</u> | 9 | 3 | 10 | >150 | 50 | >200 |
| <u>F culmorum</u> | 18 | 6 | 20 | 75 | 50 | >200 |
| <u>P digitatum</u> | >150 | >150 | 9 | >150 | >150 | >200 |
| <u>P oryzae</u> | >150 | >150 | >200 | >150 | >150 | >200 |
| <u>S tritici</u> | 9 | 2 | 37 | >150 | 60 | >200 |
| <u>T viride</u> | >150 | >150 | >200 | >150 | >150 | >200 |
| <u>V albo-atrum</u> | 9 | 3 | 37 | >150 | 100 | >200 |
| <u>V dahliae</u> | 2 | 1 | 20 | 40 | 12 | >200 |

EXAMPLE 16

Effect of ions on antifungal activity.

The effect of ions on the antifungal activity of the Rs-AFPs and Rs-nsLTP was examined in more detail. The IC_{50} values of Rs-AFP1, Rs-AFP2 and Rs-nsLTP on F culmorum and T hamatum were measured in five different media. The reference medium was the synthetic growth medium described in Example 1 which contains a total of 2.5 mM monovalent cations and 0.1 mM divalent cations. The four other media contained 10 mM KCl, 50 mM KCl, 1 mM $CaCl_2$ or 5 mM $CaCl_2$ in supplement, respectively. For the purpose of comparison, these tests were performed in parallel with β -purothionin, an antifungal protein from wheat seeds (isolated as described in Redman and Fisher, 1969, J Sci Food Agric, 20, 427-432) and Mj-AMP2, an antifungal protein from Mirabilis jalapa seeds (Cammue et al, 1992, J Biol Chem, 267, 2228-2233).

Table 6 shows the results of the antifungal activity assays in the presence of K^+ and Ca^{2+} .

Addition of KCl at up to 50 mM did not affect the antifungal activity of either Rs-AFP1 or Rs-AFP2. $CaCl_2$ at 1mM had no effect on Rs-AFP2 but increased the IC_{50} value of Rs-AFP1 by about four-fold (ie, Ca^{2+} reduced the antifungal activity of Rs-AFP1). $CaCl_2$ at 5mM almost completely inactivated Rs-AFP1 while its effect on Rs-AFP2 varied from a slight increase in IC_{50} for F culmorum to complete inactivation for T hamatum. Addition of KCl at 50 mM decreases the activity of Rs-nsLTP by more than 30-fold with both test fungi. In comparison, the IC_{50} value of β -purothionin

TABLE 6
VARIATIONS IN ANTIFUNGAL ACTIVITY IN THE PRESENCE OF K^+ AND Ca^{2+}

| Fungus | Antifungal protein | IC50 ($\mu g/ml$) Reference medium supplement: | | | | |
|-------------------|----------------------|---|------------|------------|---------------|---------------|
| | | None | 10mM K^+ | 50mM K^+ | 1mM Ca^{2+} | 5mM Ca^{2+} |
| <u>F culmorum</u> | Rs-AFP1 | 5 | 5 | 6 | 10 | 100 |
| | Rs-AFP2 | 3 | 2 | 2 | 2 | 5 |
| | Rs-nsLTP | 20 | 35 | >1000 | 108 | >1000 |
| | β -purothionin | 10 | 7 | 4 | 10 | 70 |
| | Mj-AMP2 | 4 | 5 | 40 | 50 | >100 |
| <u>T hamatum</u> | Rs-AFP1 | 7 | 7 | 7 | 30 | >100 |
| | Rs-AFP2 | 2 | 2 | 3 | 2 | >100 |
| | Rs-nsLTP | 30 | 60 | >1000 | >1000 | >1000 |
| | β -purothionin | 4 | 3 | 1.5 | 4 | 30 |
| | Mj-AMP2 | 2 | 2 | 25 | 20 | >100 |

increased by about 7-fold in the presence of 5 mM CaCl_2 . Mj-AMP2 appeared to be highly sensitive to the presence of salts, since its IC_{50} values increased by about 10-fold upon addition of either
5 1 mM CaCl_2 or 50 mM KCl.

These results show that the Rs-AFPs are antagonised by divalent cations. Rs-AFP1 is much more sensitive to the presence of divalent cations than Rs-AFP2. Rs-nsLTP is clearly more
10 salt-sensitive than either Rs-AFP1 or Rs-AFP2. The antagonistic effect of cations appears to be strongly dependent on the test organism.

15

EXAMPLE 17

Effect of the purified antimicrobial proteins on the growth of the yeast, Saccharomyces cerevisiae.

20 The purified proteins were tested for their effect on Saccharomyces cerevisiae. The method used was similar to the antifungal assay described in Example 1 except that the growth medium was YPD (10g/l yeast extract, 20g/l bactopectone, 20g/l
25 glucose) with 0.5% seaplaque agarose.

When assayed at levels of 250 $\mu\text{g/ml}$, none of the purified Brassicaceae proteins had an effect on the growth of Saccharomyces cerevisiae (strain Sp1). Similarly, Lc-AFP did not inhibit the growth
30 of S cerevisiae (strain JRY188) at a concentration of 200 $\mu\text{g/ml}$.

The Compositae and Clitoria peptides were active against the growth of S cerevisiae (strain JRY188). These results are shown in Table 7. Of

the six peptides, the two Clitoria peptides, Ct-AMP1 and Ct-AMP2 showed the highest level of activity.

5

TABLE 7

ACTIVITY OF Dm-AMPs, Cb-AMPs and Ct-AMPs on YEAST

| <u>Protein</u> | <u>IC₅₀</u> (μ g/ml) |
|----------------|--------------------------------------|
| Dm-AMP1 | 50 |
| Dm-AMP2 | 50 |
| Cb-AMP1 | 30 |
| Cb-AMP2 | 20 |
| Ct-AMP1 | 18 |
| Ct-AMP2 | 9 |

EXAMPLE 18

Effect of the purified antimicrobial proteins
20 on bacteria.

The antibacterial effect of the purified
proteins was assessed on Agrobacterium tumefaciens
C58, Alcaligenes eutrophus, Azospirillum brasilense
Sp7, Bacillus megaterium ATCC 13632, Erwinia
25 carotovora strain 3912, Escherichia coli strain
HB101, Pseudomonas solanacearum strain K60 and
Sarcina lutea ATCC 9342, using the assay described
in Example 1.

Rs-AFP2 caused 50% inhibition in B megaterium
30 at 200 μ g/ml, but had no effect on the other
bacteria at concentrations up to 500 μ g/ml.

The Compositae peptides Dm-AMP1, Dm-AMP2,
Cb-AMP1 and Cb-AMP2 showed activity only on B
megaterium where they inhibited growth to 50% at

concentrations of 180, 40, 80 and 32 $\mu\text{g/ml}$ respectively.

Rs-AFP1, Bn-AFPs, Br-AFP2, Sa-AFPs, Ct-AMPs and Lc-AFP had no effect on any of the bacteria at concentrations up to 500 $\mu\text{g/ml}$.

Results show that in general these proteins possess only weak antibacterial activity.

10

EXAMPLE 19

Effect of the purified antifungal proteins on cultured human cells.

Human cell toxicity assays were performed either on umbilical vein endothelial cells (Alessi et al, 1988, Eur J Biochem, 175, 531-540) or skin-muscle fibroblasts (Van Damme et al, 1987, Eur J Immunol, 17, 1-7) cultured in 96-well microplates. The growth medium was replaced by 80 μl of serum-free medium (Optimem 1 for endothelial cells or Eagle's minimal essential medium (EMEM) for fibroblasts, both from GIBCO), to which 20 μl of a filter-sterilised test solution was added. The cells were further incubated for 24 hours at 37°C under a 5% CO_2 atmosphere with 100 % relative humidity. The viability of the cells was assessed microscopically after staining with trypane blue (400 mg/l in phosphate buffered saline, PBS) for 10 minutes. Alternatively, cells were stained with neutral red (56 mg/l in PBS) for 2 hours at 37°C. Cells were lysed in acidic ethanol (100 mM sodium citrate, pH 4, containing 50% ethanol) and scored for release of the dye by microspectrophotometry at 540 nm.

The Rs-AFPs and Rs-nsLTP were evaluated for

their potential toxic effects using this assay. When added at up to 500 μ g/ml to either cultured human umbilical vein endothelial cells or human skin-muscle fibroblasts, neither Rs-AFP1, Rs-AFP2, nor Rs-nsLTP affected cell viability after 24 h of incubation. In contrast, β -purothionin administered at 50 μ g/ml decreased the viability of both cell types by more than 90%.

10

EXAMPLE 20

Anti-fungal activity of the Rs-AFPs against foliar disease: in vivo test

Rs-AFP2 was tested against the sugarbeet foliar disease Cercospora beticola (strain E897) using the following method.

Sugarbeet plants were grown in John Innes potting compost (No. 1 or 2) in 4cm diameter mini-pots. The protein preparation was formulated immediately prior to use by dissolving in sterile distilled water and diluting to the appropriate concentration. The formulation was applied to the plants as a foliar spray. The spray was applied to maximum discrete droplet retention. Plants were treated with the protein one day prior to inoculation with the disease which was applied as a foliar spray at a concentration of 50000 spores/ml. Plants were kept in an humidity chamber for 48 hours and then transferred to the glasshouse. Disease was assessed following a further incubation of 8 days.

Results are shown in Figure 34. The commercially available fungicide hexaconazole was used as a standard. Rs-AFP2 gave good control of

the disease and the concentration giving 50% control was approximately 15 μ M. In comparison hexaconazole gave 50% disease control when applied at approximately 7 μ M. This confirms that the protein can act as an effective fungicide in vivo and that its activity is on a molar basis comparable to the chemical standard.

10

EXAMPLE 21

Molecular cloning of Rs-AFP1 and Rs-AFP2 cDNAs

From outdoor grown Raphanus sativus plants, seeds at 6 different developmental stages were collected, frozen in liquid nitrogen and stored at -80°C. After pulverisation, total RNA was extracted from 15 g of a mixture of the 6 different developmental stages, using the method of De Vries et al (1988, Plant Molecular Biology Manual, B6, 1-13) with the exception that 6 ml of a 1:2 phenol:RNA extraction buffer mixture and 2 ml of chloroform were used per g of tissue. Poly (A)⁺ mRNA was purified by affinity chromatography on oligo(dT)-cellulose as described by Siflow et al (1979, Biochemistry 18, 2725-2731) yielding about 10 μ g of poly(A)⁺ RNA per g of tissue. Double stranded cDNAs were prepared from 1,5 μ g of poly(A)⁺ RNA according to Gubler and Hoffman (1983, Gene 25, 263-269) and ligated to EcoRI/NotI adaptors using the cDNA Synthesis Kit of Pharmacia. The cDNAs were cloned into the lambda ZAPII phage vector (Stratagene) according to the manufacturers instructions. A DNA probe for screening the cDNA library was produced by polymerase chain reaction (PCR) as follows. Two degenerate oligonucleotides

30

were synthesised:

OWB15 (5'AAAGAATTCAARYTNTGYSARMGNCC 3') and

OWB17 (5'AAAGAATTCRTGNGCNGGRAANACRTARTTRC 3').

OWB15 corresponds to amino acids 2 to 7 of Rs-AFP1

5 and has a sense orientation. OWB17 corresponds to amino acids 36 to 43 of Rs-AFP1 and has an antisense orientation. Both primers have the AAAGAATTC (i.e. AAA followed by the EcoRI

10 PCR was performed with the Taq polymerase under standard conditions (Sambrook et al, 1989, Molecular Cloning, Cold Spring Harbor Laboratory Press) using OWB15 and OWB17 as amplimers and 25 ng of cDNA as target DNA. The temperature programme
15 included an initial step at 94°C for 5 min, 30 cycles (94°C for 1 min; 45°C for 2 min, 72°C for 3 min) and a final step at 72°C for 10 min. The 144 bp PCR amplification product was purified on a 3% agarose (NuSieve, FMC) gel. This PCR product was
20 partially reamplified using the sense degenerate oligonucleotide OWB16

(5'AAAGAATTCGGNACNTGGWSNNGNGTNTG 3') and OWB17.

OWB16 also has the AAAGAATTC extension at its 5' end. This 123 bp PCR amplification product was
25 again purified on a 3% agarose (NuSieve, FMC) gel and reamplified by PCR under the same conditions except that the reaction mixture contained 130 μ M dTTP and 70 μ M digoxigenin-11-dUTP instead of 200 μ M dTTP. The digoxigenin-labeled PCR product was
30 purified on a 3% NuSieve agarose gel.

About 10,000 plaque forming units of the lambda ZAPII cDNA library were screened with the digoxigenin-labeled PCR product by in situ plaque hybridisation using nylon membranes (Hybond-N,

Amersham). Membranes were air-dried and DNA was crosslinked to the membranes under UV light (0.15 J/cm^2). Hybridisation was performed for 16 h at 64°C in $5 \times \text{SSC}$, 1 % blocking reagent (Boehringer Mannheim), 0.1 % N-lauroylsarcosine, 0.02 % sodium dodecylsulphate containing 10 ng/ml of heat denatured digoxigenin-labeled probe. Non-specifically bound probe was removed by rinsing two times 5 min in $2 \times \text{SSC} / 0.1 \%$ SDS at 25°C and two times 15 min in $0.1 \times \text{SSC} / 0.1 \%$ SDS at 60°C . Detection of the probe was done using anti-digoxigenin antibodies linked to alkaline phosphatase (Boehringer Mannheim) and its substrate 5-bromo-4-chloro-3-indolyl phosphate (Boehringer Mannheim) according to the manufacturers instructions. Positive plaques were purified by two additional screening rounds with the same probe under the same conditions. Inserts from purified plaques were excised in vivo into the pBluescript phagemid form with the aid of the helper phage R408. The inserts from 22 different positive clones were excised by EcoRI digestion and their sizes compared by agarose gel electrophoresis. Four clones had an insert of approximately 400 bp, the other 18 positive clones contained inserts ranging between approximately 250 and 300 bp. The four clones with the 400 bp inserts and six clones with the smaller inserts were subjected to nucleotide sequence analysis. The clones with the largest insert all had an open reading frame of 80 amino acids corresponding to Rs-AFP1, as could be determined by comparison to the experimental N-terminal amino acid sequences (see Example 12). The 243 bp open reading frames code for the mature

Rs-AFP1 (50 amino acids) preceded by a putative 29 amino acid signal sequence obeying the (-1,-3) rule (von Heijne 1985, Mol. Biol. 184, 99-105). These full-length cDNA clones only differed from each other in the length of their 5' and 3' end untranslated regions. Five of the clones with the smallest insert were partially identical to the full-length Rs-AFP1 cDNA clones except that they were truncated at their 5' ends. The remaining clone was identified as a 5' truncated Rs-AFP2 cDNA clone by comparing the deduced and the experimentally determined amino acid sequences. When comparing the full-length Rs-AFP1 cDNA clone pFRG1 (Fig. 35) and the truncated Rs-AFP2 cDNA clone pFRG2 (Fig. 36), it can be seen that the codon usage is slightly different and that the 3' end untranslated region of the Rs-AFP2 cDNA is longer than the one of the Rs-AFP1 cDNA. Finally, both the Rs-AFP1 and the Rs-AFP2 cDNA clones have at least two polyadenylation signals. Figure 35 shows the nucleotide sequence and the deduced amino acid sequence of the full-length Rs-AFP1 cDNA clone pFRG1. The putative signal sequence is underlined and the sequence of the mature Rs-AFP1 is boxed. Figure 36 shows the nucleotide sequence and the deduced amino acid sequence of the 5' truncated Rs-AFP2 cDNA clone pFRG2.

In order to obtain a full-length Rs-AFP2 cDNA, another approach was followed : PCR was performed under standard conditions using the antisense oligonucleotide OWB23 (5'ATAGAATTTCGACGTGAGCTTATCATCTTATTATCCG 3') in combination with the M13 universal primer at one

hand and the M13 reverse primer at the other hand. The last 30 nucleotides of OWB23 form the inverted complementary sequence of the part of the 3' untranslated region immediately flanking the poly-A tail of pFRG2 (see Fig. 36). This sequence is extended to the 5' end with the GAATTC EcoRI recognition site preceded by the nucleotides 'ATA'. As a template, either 2 μ g of total cDNA or 10^5 recombinant phages were used. In both cases, 3 separate reactions were set up. Prior to amplification, phages were lysed by an initial step in the PCR temperature programme of 5 min at 99°C to liberate the phage DNA. The size of the amplification products was determined by electrophoresis on a 3% agarose (NuSieve, FMC) gel. Products were obtained with sizes corresponding to inserts of 280 to 300 bp. Thus, it can be concluded that no full-length Rs-AFP2 cDNA clones seem to be present in the cDNA library.

20

EXAMPLE 22

Mutagenesis of Rs-AFP1 cDNA to Rs-AFP2 DNA

As can be deduced from the experimentally determined N-terminal sequences (see Example 12) and the nucleotide sequences (see Example 21), Rs-AFP1 and Rs-AFP2 only differ in two amino acids as stated in Example 12. As the antifungal potency of Rs-AFP2 is significantly higher than that of Rs AFP1 (see Table 1) and a full-length cDNA clone of the Rs-AFP2 is not available, the Rs-AFP1 cDNA was transformed into the Rs-AFP2 nucleotide sequence by PCR-assisted site-directed mutagenesis according to the method of E. Merino et al (1992, BioTechniques

25

30

12, 508-510). The following oligonucleotides were used :

OWB28 (5'CTTGGCCTTTGGCACAACTTC 3'),

OWB29 (5'GCTTTCTCAAGTCTAATGCAC 3'),

5 OWB30

(5'AACTCGAGCTGCAGTGTGACCTATTAACAAGGAAAGTAGC 3'),

OWB35

(5'GGAATAGCCGATCGAGATCTAGGAAACAGCTATGACCATG 3'),

OWB36 (5'GGAATAGCCGATCGAGATCTAGGA3').

10 The first mutation (glutamate into glutamine at position 5 of the mature protein) was introduced by performing PCR with the Pfu polymerase (Stratagene) using OWB35 (this is the M13 universal primer with a 5' tag sequence) and OWB28 (the first
15 antisense mutagenesis primer) as amplimers and 100 ng of the KpnI-digested pFRG1 cDNA as target DNA. $MgCl_2$ was added to the amplification mixture to a final concentration of 50 mM. The temperature programme included an initial step at 94°C for
20 5 min, 30 cycles (94°C for 1 min, 45°C for 2 min, 72°C for 3 min) and a final step at 72°C for 10 min. In a second step, this PCR product was used as a megaprimer and extended by the Pfu polymerase using 50 ng of the KpnI-digested pFRG1 cDNA as the
25 target DNA. The temperature programme included an initial step at 94°C for 5 min followed by a 5 cycles extension (94°C for 1 min, 50°C for 1 min, 72°C for 1 min). Then OWB29 (the antisense primer introducing the second mutation, from asparagine to
30 arginine at position 27 of the mature protein) and OWB36 (which is identical to the 5' tag sequence of OWB35) were added, followed by PCR amplification by the Pfu-polymerase as described for the introduction of the first mutation. To get a full-

length Rs-AFP2 nucleotide sequence, the procedure outlined in the second step was repeated though using the oligonucleotide primers OWB36 and OWB30 (which introduces a second stop codon followed by the SalI, PstI and XhoI restriction sites, thus also eliminating the 3' end untranslated region of the Rs-AFP1 cDNA clone pFRG1). The final PCR product was cut with BamHI (occurring in the polylinker of the pBluescript phagemid pFRG1) and SalI, subcloned in pEMBL18+ (pre-digested with the same restriction enzymes) and subjected to nucleotide sequence analysis. Figure 37 shows the nucleotide sequence and the derived amino acid sequence of the full-length Rs-AFP2 DNA clone pFRG4 obtained by PCR-assisted site-directed mutagenesis of the Rs-AFP1 cDNA clone pFRG1. The putative signal sequence is underlined and the sequence of the mature Rs-AFP2 is boxed.

20

EXAMPLE 23

Construction of the expression vector pFRG7

The expression vector pFRG7 (Figure 38; SP = signal peptide, MP = mature protein) contains the full coding region of the Rs-AFP2 DNA flanked at its 5' end by the strong constitutive promoter of the 35S RNA of the cauliflower mosaic virus (Odell et al, 1985, Nature 313, 810-812) with a duplicated enhancer element to allow for high transcriptional activity (Kay et al, 1987, Science 236, 1299-1302). The coding region of the Rs-AFP2 DNA is flanked at its 3' end side by the polyadenylation sequence of 35S RNA of the cauliflower mosaic virus (CaMV35S). The plasmid backbone of this vector is the phagemid

25

30

pUC120 (Vieira and Messing 1987, Methods Enzymol. 153, 3-11). pFRG7 was constructed as follows : clone pFRG4 which consisted of the Rs-AFP2 DNA (Figure 37) cloned into the BamHI / SalI sites of
5 pEMBL18+, Boehringer). The 298 bp BamHI / SalI fragment was subcloned into the expression vector pFAJ3002 which was pre-digested with BamHI and SalI. pFAJ3002 is a derivative of the expression vector pFF19 (Timmermans et al, 1990, J.
10 Biotechnol. 14, 333-344) of which the unique EcoRI site is replaced by a HindIII site.

EXAMPLE 24

15 Construction of the plant transformation vector pFRG8

The expression vector pFRG7 was digested with HindIII and the fragment containing the Rs-AFP2 DNA expression cassette was subcloned into the unique
20 HindIII site of pBin19Ri. pBin19Ri is a modified version of the plant transformation vector pBin19 (Bevan 1984, Nucleic Acids Research 12, 8711-8721) wherein the unique EcoRI and HindIII sites are switched and the defective nptII
25 expression cassette (Yenofsky et al. 1990, Proc. Natl. Acad. Sci. USA 87: 3435-3439) is introduced. The new plant transformation vector is designated pFRG8 (Figure 39).

EXAMPLE 25

Plant Transformation

The disarmed Agrobacterium tumefaciens strain LBA4404 (pAL4404) (Hoekema et al, 1983, Nature 303, 179-180) was transformed with the vector pFRG8 using the method of de Framond et al (BioTechnology 1, 262-269).

Tobacco transformation was carried out using leaf discs of Nicotiana tabacum Samsun based on the method of Horsch et al (1985, Science 227, 1229-1231) and co-culturing with Agrobacterium strains containing pFRG8. Co-cultivation was carried out under selection pressure of 100 μ g/ml kanamycin. Transgenic plants (transformed with pFRG8) were regenerated on media containing 100 μ g/ml kanamycin. These transgenic plants may be analysed for expression of the newly introduced genes using standard western blotting techniques. Plants capable of constitutive expression of the introduced genes may be selected and self-pollinated to give seed. F1 seedlings of the transgenic plants may be further analysed.

CLAIMS

- 1 An antimicrobial protein having substantially
5 the amino acid sequence shown in Figures 27 to
29 or in Figure 32.
- 2 A protein as claimed in claim 1 which is an
10 oligomer and which comprises at least one
polypeptide having substantially the amino
acid sequence shown in Figures 27 to 29 or
in Figure 32.
- 3 A protein as claimed in claim 1 or claim 2
15 which is capable of being isolated from a
plant seed.
- 4 A protein as claimed in claim 3 which is
20 capable of being isolated from a seed of the
family Brassicaceae or of the family
Compositae or of the family Leguminosae.
- 5 A protein as claimed in claim 4 which is
isolated from Raphanus, Brassica, Sinapis,
25 Arabidopsis, Dahlia, Cnicus, Lathyrus or
Clitoria.
- 6 A pure protein Rs-AFP1, capable of being
isolated from Raphanus seed.
- 30 7 A pure protein Rs-AFP2, capable of being
isolated from Raphanus seed.


- 8 A pure protein Rs-nsLTP, capable of being isolated from Raphanus seed.
- 5 9 Pure proteins Bn-AFP1, Bn-AFP2, Br-AFP1 and Br-AFP2, capable of being isolated from Brassica seed.
- 10 10 Pure proteins Sa-AFP1 and Sa-AFP2, capable of being isolated from Sinapis seed.
- 10 11 A pure protein At-AFP1, capable of being isolated from Arabidopsis seed.
- 15 12 A pure protein Dm-AMP1, capable of being isolated from Dahlia seed.
- 13 A pure protein Dm-AMP2, capable of being isolated from Dahlia seed.
- 20 14 A pure protein Cb-AMP1, capable of being isolated from Cnicus seed.
- 15 A pure protein Cb-AMP2, capable of being isolated from Cnicus seed.
- 25 16 A pure protein Lc-AFP, capable of being isolated from Lathyrus seed.
- 30 17 A pure protein Ct-AMP1, capable of being isolated from Clitoria seed.
- 18 A pure protein Ct-AMP2, capable of being isolated from Clitoria seed.

- 19 A protein as claimed in any of claims 1 to 18 which is synthetic.
- 5 20 A recombinant DNA sequence encoding a protein as claimed in any of claims 1-19.
- 21 A DNA sequence as claimed in claim 20 which is a cDNA.
- 10 22 A DNA sequence as claimed in claim 20 which is genomic DNA.
- 23 A DNA sequence as claimed in claim 22 which is isolated from a plant genome.
- 15 24 A DNA sequence as claimed in claim 23 which includes a promoter sequence.
- 20 25 A promoter sequence obtainable from a gene encoding a protein as claimed in any of claims 1-19.
- 26 A vector containing a DNA sequence as claimed in claim 20.
- 25 27 A biological system including recombinant DNA as claimed in claim 20 such that the encoded protein is expressed.
- 30 28 A biological system as claimed in claim 27 which is a micro-organism.
- 29 A biological system as claimed in claim 27 which is a plant.

- 30 An antimicrobial protein produced by
expression of recombinant DNA as claimed in
claim 20.
- 5 31 A plant transformed with recombinant DNA as
claimed in claim 20.
- 10 32 A plant as claimed in claim 26 in which the
recombinant DNA encodes at least one of the
following proteins: Rs-AFP1, Rs-AFP2,
Rs-nsLTP, Bn-AFP1, Bn-AFP2, Br-AFP1, Br-AFP2,
Sa-AFP1, Sa-AFP2, At-AFP1, Dm-AMP1, Dm-AMP2,
Cb-AMP1, Cb-AMP2, Lc-AFP, Ct-AMP1, Ct-AMP2.
- 15 33 Seeds and progeny of a plant as claimed in
claim 31 or claim 32.
- 20 34 A composition containing at least one of the
proteins as claimed in any of claims 1 to 19
or claim 30.
- 25 35 A process of combating fungi or bacteria which
comprises exposure to a protein or composition
as claimed in any of claims 1 to 19, claim 30
or claim 34.
- 30 36 A process of combating fungi or bacteria which
comprises exposure to a protein encoded by pea
gene pI39, by pea gene pI230, by cowpea gene
pSAS10, or by potato gene pI322.
- 37 37 A process of combating fungi or bacteria which
comprises exposure to SI α 2, γ -l-purothionin,
or another α -amylase inhibitor protein.


- 38 An extraction process for producing a protein
as claimed in any of claims 1 to 19 or claim
30 from organic material containing them which
comprises submitting the organic material to
maceration and solvent extraction.
- 39 An extraction process as claimed in claim 38
where the protein is subsequently purified by
centrifugation, chromatography and dialysis.
- 40 An extraction process as claimed in either
claim 38 or claim 39 where the organic matter
comprises seeds of Raphanus, Brassica,
Sinapis, Arabidopsis, Dahlia, Cnicus, Lathyrus
or Clitoria.
- 41 An extraction process as claimed in either
claim 38 or claim 39 where the organic matter
comprises a biological system as claimed in
claim 27.
- 42 A process for producing a protein as claimed
in any of claims 1 to 19 which comprises
chemical synthesis of the protein.
- 43 A process for producing a protein as claimed
in any of claims 1 to 19 which comprises
expression of a recombinant DNA sequence
encoding the protein.

FIG. 1




2 / 4 2

FIG. 2A




3 / 4 2

FIG. 2B



SUBSTITUTE SHEET

4 / 4 2

FIG. 3

5 / 4 2





FIG. 4

SUBSTITUTE SHEET

FIG. 5



SUBSTITUTE SHEET





FIG. 6

8 / 4 2

FIG. 7



SUBSTITUTE SHEET






FIG. 8

SUBSTITUTE SHEET



SUBSTITUTE SHEET






1

2

3

4

FIG. 11



SUBSTITUTE SHEET

FIG. 12






FIG. 13



SUBSTITUTE SHEET

15 / 42


FIG. 14



SUBSTITUTE SHEET

16 / 42

FIG. 15



SUBSTITUTE SHEET

FIG. 16






FIG. 17



SUBSTITUTE SHEET

FIG. 18



SUBSTITUTE SHEET

FIG. 19






FIG. 20



22 / 42

FIG. 21



SUBSTITUTE SHEET

23 / 42

FIG. 22





FIG. 23



24 / 42

FIG. 24



FIG. 25





FIG. 26



SUBSTITUTE SHEET

FIG. 27

Rs-AFP1 (Q) K L C E R P S G T W S G V C G N N

Rs-AFP2 (Q) K L C Q R P S G T W S G V C G N N

INACKNQCINLEKARHGSCNYVFPAHK

INACKNQCIRLEKARHGSC

Br-AFP1

Br-AFP2 ? R

Bn-AFP1

Bn-AFP2

Sa-AFP1

Sa-AFP2 Q R

At-AFP1 S

FIG. 28

| | | | | | | | | | | | | | | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Dm-AMP1 | E | L | C | E | K | A | S | K | T | W | S | G | N | C | G | N | T | G | H | C | D | N |
| Dm-AMP2 | E | V | C | E | K | A | S | K | T | W | S | G | N | C | G | N | T | G | H | C | | |
| Cb-AMP1 | E | L | C | E | K | A | S | K | T | W | S | G | N | C | G | N | T | K | H | C | D | D |
| Cb-AMP2 | E | L | C | E | K | A | S | K | T | W | S | G | N | C | G | N | T | K | H | C | D | N |
| Q C K S W E G A A H G A C H V R N G K H M C F C Y F N C | | | | | | | | | | | | | | | | | | | | | | |
| Q C K S W E G A A H G A C H V R N G K H M C F C Y F N C | | | | | | | | | | | | | | | | | | | | | | |
| K C K S W E G A A H G A C H V R S G K H M C F C Y F N C | | | | | | | | | | | | | | | | | | | | | | |

27 / 42

FIG. 29

LC-AFP K T C E N L S G T F K G P C I P D G N C N K H C K N

Ct-AMP1 N L C E R A S L T W T G N C G N T G H C D T Q C R N

N E H L L S G R C R D D F ? - - C W C T R N C

W E S A K H G A C H K R G N W K C F C Y F D C

FIG. 30 (1/3)


| | | | | | | | | | | | | | | | | | | | | |
|---------------|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Rs-AFP1 (Q) | K | L | C | E | R | P | S | G | T | W | S | G | V | C | G | N | N | N | A | C |
| Dm-AMP1 | E | L | C | E | K | A | S | K | T | W | S | G | N | C | G | N | T | G | H | C |
| Cb-AMP1 | E | L | C | E | K | A | S | K | T | W | S | G | N | C | G | N | T | K | H | C |
| Cb-AMP2 | E | L | C | E | K | A | S | K | T | W | S | G | N | C | G | N | T | K | H | C |
| Lc-AFP | K | T | C | E | N | L | S | G | T | F | K | G | P | C | I | P | D | G | N | C |
| Ct-AMP1 | N | L | C | E | R | A | S | L | T | W | T | G | N | C | G | N | T | G | H | C |
| pI230 | N | T | C | E | N | L | A | G | S | Y | K | G | V | C | F | G | G | - | - | C |
| pI39 | N | T | C | E | H | L | A | D | T | Y | R | G | V | C | F | T | N | A | S | C |
| pSAS10 | K | T | C | E | L | N | A | D | T | Y | R | G | P | C | F | T | T | G | S | C |
| pI322 | R | H | C | E | S | L | S | H | R | F | K | G | P | C | T | R | D | S | N | C |
| SI α 2 | R | V | C | M | G | K | S | A | G | F | K | G | L | C | M | R | D | Q | N | C |
| γ 1pur | K | I | C | R | R | R | S | A | G | F | K | G | P | C | M | S | N | K | N | C |

SUBSTITUTE SHEET

FIG. 30 (2/3)

| | | | | | | | | | | | | | | | | | | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| K | N | Q | C | I | N | L | E | K | A | R | H | G | S | C | N | Y | V | F |
| D | N | Q | C | K | S | W | E | G | A | A | H | G | A | C | H | V | R | N |
| D | D | Q | C | K | S | W | E | G | A | A | H | G | A | C | H | V | R | N |
| D | N | K | C | K | S | W | E | G | A | A | H | G | A | C | H | V | R | S |
| N | K | H | C | K | N | N | E | H | L | L | S | G | R | C | R | D | D | F |
| D | T | Q | C | R | N | W | E | S | A | K | H | G | A | C | H | K | R | - |
| D | R | H | C | R | T | Q | E | G | A | I | S | G | R | C | R | D | D | F |
| D | D | H | C | K | N | K | A | H | L | I | S | G | T | C | H | - | D | W |
| D | D | H | C | K | N | K | E | H | L | L | S | G | R | C | R | - | D | D |
| A | S | V | C | E | T | - | E | R | F | S | G | G | N | C | H | - | G | F |
| A | Q | V | C | L | - | Q | E | G | W | G | G | G | N | C | D | G | V | M |
| A | Q | V | C | Q | - | Q | E | G | W | G | G | G | N | C | D | G | P | F |

FIG. 30 (3/3)



SUBSTITUTE SHEET

FIG. 31A(1/2)

| | |
|---------|---|
| Dm-AMP1 | GAG CTT TGC GAG AAG GCT TCT AAG ACT TGG TCT GGA AAC |
| | TGG GAG GGA GCT GCT CAT GGA GCT TGC CAT GTT AGA AAC |
| Dm-AMP2 | GAG GTT TGC GAG AAG GCT TCT AAG ACT TGG TCT GGA AAC |
| Cb-AMP1 | GAG CTT TGC GAG AAG GCT TCT AAG ACT TGG TCT GGA AAC |
| | TGG GAG GGA GCT GCT CAT GGA GCT TGC CAT GTT AGA AAC |
| Cb-AMP2 | GAG CTT TGC GAG AAG GCT TCT AAG ACT TGG TCT GGA AAC |
| | TGG GAG GGA GCT GCT CAT GGA GCT TGC CAT GTT AGA TCT |

SUBSTITUTE SHEET

FIG. 31A(2/2)

TGC GGA AAC ACT GGA CAT TGC GAT AAC CAA TGC AAG TCT

GGA AAG CAT ATG TGC TTC TGC TAC TTC AAC TGC

TGC GGA AAC ACT GGA CAT TGC

TGC GGA AAC ACT AAG CAT TGC GAT GAT CAA TGC AAG TCT

GGA AAG CAT ATG TGC TTC TGC TAC TTC AAC TGC

TGC GGA AAC ACT AAG CAT TGC GAT AAC AAG TGC AAG TCT

GGA AAG CAT ATG TGC TTC TGC TAC TTC AAC TGC

SUBSTITUTE SHEET

33 / 42

FIG. 31B

Lc-AFP

AAG ACT TGC GAG AAC CTT TCT GGA ACT TTC AAG GGA CCA

AAC GAG CAT CTT CTT TCT GGA AGA TGC AGA GAT GAT TTC

Ct-AMP1

AAC CTT TGC GAG AGA GCT TCT CTT ACT TGG ACT GGA AAC

TGG GAG TCT GCT AAG CAT GGA GCT TGC CAT AAG AGA GGA

TGC ATT CCA GAT GGA AAC TGC AAC AAG CAT TGC AAG AAC

??? TGC TGG TGC ACT AGA AAC TGC

TGC GGA AAC ACT GGA CAT TGC GAT ACT CAA TGC AGA AAC

AAC TGG AAG TGC TTC TGC TAC TTC GAT TGC

SUBSTITUTE SHEET

3 4 / 4 2

FIG. 32

Rs-nsLTP A L S C G T V N S N L A A C I G Y L T Q
 N A P L A R G C C T G V T N L N N M A ? T T P

FIG. 33 (1/2)

| | | | | | |
|----------|-------|-------|-------|-------------------|-----|
| Rs-nsLTP | A L S | C G T | V N S | N L A A C I G Y L | T Q |
| So-nsLTP | G I T | C G M | V S S | L A P C I G Y L | K G |
| Rc-nsLTP | V D | C G Q | V N S | L A S C I P F L | T G |
| Dc-nsLTP | V L T | C G Q | V T G | L A P C L G Y L | R S |
| Hv-nsLTP | A L N | C G Q | V D S | N K P C L T Y V | Q G |
| Zm-nsLTP | A I S | C G Q | V A S | I A P C I S Y A | R G |


SUBSTITUTE SHEET

FIG. 33 (2/2)

| | | | | | | | | |
|-------------|-----|-------|-------------|-----|---------|-----|-------|-----|
| N - A - - - | P L | A R G | C C T G V | T N | L N N M | A ? | T T P | ... |
| G - - - - | P L | G G S | G G I K | A L | N A A | A | T T P | ... |
| G V A S - - | P S | A S - | C C A G V Q | N L | K T L A | P | T S A | ... |
| Q V N V P V | P L | T - - | C C N V V R | G L | N N A | A R | T T L | ... |
| G P G - G - | P S | G L - | C C N G V R | D L | H N Q | A Q | S S G | ... |
| Q - G S G - | P S | A - G | C C S G V R | S L | N N A | A R | T T A | ... |

36 / 42

FIG. 34



SUBSTITUTE SHEET

37 / 42

GTTTTATTAGTGATCAIGGCTAAGTTTGCGTGCCATCATCGCACTT 45
 M A K F A S I I A L

 CTTTTGCTGCTCTTGTCTCTTTTGTCTGCTTTTCGAAGCACCAACA 90
 L F A A L V L F A A F E A E T

 ATGGTGGAAGCACAGAAAGTTGTGCGAAAGGCCAAGTGGGACATGG 135
 M V E A [Q K L C E R P S G T W]

 TCAGGAGTCTGTGGAAACAATAACGCATGCAAGAATCAGTGCATT 180
 [S G V C G N N N A C K N Q C I]

 AACCTTGAGAAAGCACGACATGGATCTTGCAACTATGTCTTCCCA 225
 [N L E K A R H G S C N Y V F P]

 GTCACAAGTGTAATCTGCTACTTTCCCTTGTIAAATTTATCGCAAAC 270
 [A H K C I C Y F P C] *

 TCTTTGGTGAATAGTTTTATGTAATTTACACAAATAAGTCAGT 315

 GTCATATCCATGAGTGATTTTAAGACATGTACCAGATATGTTAT 360

 GTTGGTTCGGTTATACAAATAAAGTTTTATTACCCAAAAAAA 405

 AAAAAAAA 414

FIG. 35

38 / 42

FIG. 36

| | |
|--|-----|
| GGAATAATAACGCATGCAAGAATCAGTGCAATTCGACTTGAGAAA | 45 |
| G N N A C K N Q C I R L E K | |
| GCACGACATGGGTCTTGCAACTATGTCTTCCAGCTCACAAAGTGT | 90 |
| A R H G S C N Y V F P A H K C | |
| ATCTGTTATTTCCCTTGT <u>IAA</u> TTCCATAAACTCTTCGGTGGTTAA | 135 |
| I C Y F P C * | |
| TAGTGCGGCATATTACATATAATTAATAAGTTTGIGTCACTATT | 180 |
| TATTAGTGACTTTATGACATGTGCCAGGTATGTTTATGTTGGGTT | 225 |
| GGTTGTAATATAAAAAGTTCACGGATAATAAGATGATAAGCTCA | 270 |
| CGTCGCCCAAAAAA | 284 |

40 / 42

FIG. 37 (2/2)

130 | 140 | 150 | 160 | 170 | 180 |
 CCAAGTGGACATGGTCAGGAGTCTGTGGAAACAATAACGCATGCAAGAAATCAGTGCATT

P S G T W S G V C G N N N A C K N Q C I

190 | 200 | 210 | 220 | 230 | 240 |
 AGACTTGAGAAAGCACGACATGGATCTTGCAACTATGTCTTCCAGCTCACAAGTGATC


R L E K A R H G S C N Y V F P A H K C I

250 | 260 |
 TGCTACTTTCCTTGTTAATAG

C Y F P C - -


SUBSTITUTE SHEET

FIG. 38



42 / 42

FIG. 39



SUBSTITUTE SHEET

International Application No

PCT/GB 92/01570

| I. CLASSIFICATION OF SUBJECT MATTER (if several classification symbols apply, indicate all) ⁶ According to International Patent Classification (IPC) or to both National Classification and IPC Int.Cl. 5 C12N15/29; C07K7/10; C12N15/82; A01N65/00 A01H5/00; C12N5/10; C12N1/21 | | | | | | | | | | | |
|---|---|-------------------------------------|-------------|---|--|---|--|---|--------|--|---|
| II. FIELDS SEARCHED Minimum Documentation Searched ⁷ <table border="1"> <tr> <td>Classification System</td> <td colspan="3">Classification Symbols</td> </tr> <tr> <td>Int.Cl. 5</td> <td>C12N ;</td> <td>C07K ;</td> <td>A01N ; A01H</td> </tr> </table> Documentation Searched other than Minimum Documentation to the Extent that such Documents are Included in the Fields Searched ⁸ | | | | Classification System | Classification Symbols | | | Int.Cl. 5 | C12N ; | C07K ; | A01N ; A01H |
| Classification System | Classification Symbols | | | | | | | | | | |
| Int.Cl. 5 | C12N ; | C07K ; | A01N ; A01H | | | | | | | | |
| III. DOCUMENTS CONSIDERED TO BE RELEVANT⁹ <table border="1"> <tr> <th>Category^o</th> <th>Citation of Document, ¹¹ with indication, where appropriate, of the relevant passages ¹²</th> <th>Relevant to Claim No.¹³</th> </tr> <tr> <td>X</td> <td> CHEMICAL ABSTRACTS, vol. 77, 1972, Columbus, Ohio, US; abstract no. 70756, FERNANDEZ DE CALEYA, R., ET AL 'Susceptibility of phytopathogenic bacteria to wheat purothionins in vitro' see abstract & APPL. MICROBIOL. vol. 23, no. 5, 1972, pages 998 - 1000 <div style="text-align: center;">---</div> <div style="text-align: right;">-/--</div> </td> <td>37</td> </tr> </table> <p>^o Special categories of cited documents : ¹⁰</p> <table border="0"> <tr> <td style="vertical-align: top;"> <p>"A" document defining the general state of the art which is not considered to be of particular relevance</p> <p>"E" earlier document but published on or after the international filing date</p> <p>"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</p> <p>"O" document referring to an oral disclosure, use, exhibition or other means</p> <p>"P" document published prior to the international filing date but later than the priority date claimed</p> </td> <td style="vertical-align: top;"> <p>"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</p> <p>"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step</p> <p>"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.</p> <p>"&" document member of the same patent family</p> </td> </tr> </table> | | | | Category ^o | Citation of Document, ¹¹ with indication, where appropriate, of the relevant passages ¹² | Relevant to Claim No. ¹³ | X | CHEMICAL ABSTRACTS, vol. 77, 1972, Columbus, Ohio, US; abstract no. 70756, FERNANDEZ DE CALEYA, R., ET AL 'Susceptibility of phytopathogenic bacteria to wheat purothionins in vitro' see abstract & APPL. MICROBIOL. vol. 23, no. 5, 1972, pages 998 - 1000 <div style="text-align: center;">---</div> <div style="text-align: right;">-/--</div> | 37 | <p>"A" document defining the general state of the art which is not considered to be of particular relevance</p> <p>"E" earlier document but published on or after the international filing date</p> <p>"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</p> <p>"O" document referring to an oral disclosure, use, exhibition or other means</p> <p>"P" document published prior to the international filing date but later than the priority date claimed</p> | <p>"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</p> <p>"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step</p> <p>"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.</p> <p>"&" document member of the same patent family</p> |
| Category ^o | Citation of Document, ¹¹ with indication, where appropriate, of the relevant passages ¹² | Relevant to Claim No. ¹³ | | | | | | | | | |
| X | CHEMICAL ABSTRACTS, vol. 77, 1972, Columbus, Ohio, US; abstract no. 70756, FERNANDEZ DE CALEYA, R., ET AL 'Susceptibility of phytopathogenic bacteria to wheat purothionins in vitro' see abstract & APPL. MICROBIOL. vol. 23, no. 5, 1972, pages 998 - 1000 <div style="text-align: center;">---</div> <div style="text-align: right;">-/--</div> | 37 | | | | | | | | | |
| <p>"A" document defining the general state of the art which is not considered to be of particular relevance</p> <p>"E" earlier document but published on or after the international filing date</p> <p>"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</p> <p>"O" document referring to an oral disclosure, use, exhibition or other means</p> <p>"P" document published prior to the international filing date but later than the priority date claimed</p> | <p>"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</p> <p>"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step</p> <p>"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.</p> <p>"&" document member of the same patent family</p> | | | | | | | | | | |
| IV. CERTIFICATION <table border="1"> <tr> <td> Date of the Actual Completion of the International Search 25 NOVEMBER 1992 </td> <td> Date of Mailing of this International Search Report 09. 12. 92. </td> </tr> <tr> <td> International Searching Authority EUROPEAN PATENT OFFICE </td> <td> Signature of Authorized Officer MADDOX A.D. </td> </tr> </table> | | | | Date of the Actual Completion of the International Search 25 NOVEMBER 1992 | Date of Mailing of this International Search Report 09. 12. 92. | International Searching Authority EUROPEAN PATENT OFFICE | Signature of Authorized Officer MADDOX A.D. | | | | |
| Date of the Actual Completion of the International Search 25 NOVEMBER 1992 | Date of Mailing of this International Search Report 09. 12. 92. | | | | | | | | | | |
| International Searching Authority EUROPEAN PATENT OFFICE | Signature of Authorized Officer MADDOX A.D. | | | | | | | | | | |

| III. DOCUMENTS CONSIDERED TO BE RELEVANT (CONTINUED FROM THE SECOND SHEET) | | Relevant to Claim No. |
|--|---|-----------------------|
| Category ° | Citation of Document, with indication, where appropriate, of the relevant passages | |
| A | CHEMICAL ABSTRACTS, vol. 97, 1982, Columbus, Ohio, US; abstract no. 108755, JONES, B.L., ET AL. 'Inactivation of alpha-amylase activity by purothionins' see abstract & CEREAL CHEM. vol. 59, no. 4, 1982, page 321 --- | 37 |
| A | BIOLOGICAL ABSTRACTS RRM DOCUMENT NO. BR41:2924 see abstract & MEM. COLL. AGRIC. EHIME UNIV. vol. 35, no. 2, 1991, pages 131 - 138 OHGUCHI, T., ET AL. 'Antifungal action of the homogenate of japanese radish' --- | 5 |
| A | EMBO JOURNAL vol. 7, no. 6, 1988, EYNSHAM, OXFORD GB pages 1559 - 1565 BOHLMANN, H., ET AL. 'Leaf-specific thionins of barley - a novel class of cell wall proteins toxic to plant-pathogenic fungi and possibly involved in the defense mechanism of plants' see the whole document --- | 35-38,43 |
| A | EP,A,0 375 091 (INSTITUT GENBIOLOGISCHE FORSCHUNG BERLIN) 27 June 1990 see example 6 --- | 27,29,31 |
| A | WO,A,9 011 770 (CALGENE) 18 October 1990 see the whole document --- | 27,29,31 |
| A | J. EXP. BOT., 238 SUPPLEMENT, MEETING HELD APRIL 7 - 12, 1991. vol. 42, 1991, page 4 GARCIA-OLMEDA, F. 'Trypsin alpha amylase inhibitors and thionins from cereals: possible role in crop protection' see abstract P1.5 --- | 37 |
| | --- | -/-- |

III. DOCUMENTS CONSIDERED TO BE RELEVANT

(CONTINUED FROM THE SECOND SHEET)

| Category ° | Citation of Document, with indication, where appropriate, of the relevant passages | Relevant to Claim No. |
|------------|--|------------------------------|
| P,X | JOURNAL OF BIOLOGICAL CHEMISTRY vol. 267, no. 22, 5 August 1992, BALTIMORE, MD US pages 15301 - 15309 TERRAS, F.R.G., ET AL. 'Analysis of two novel classes of plant antifungal proteins from Radish (<i>Raphanus sativus</i> L.) seeds' see the whole document ----- | 1-7, 30, 34, 35, 38-40 |

**ANNEX TO THE INTERNATIONAL SEARCH REPORT
ON INTERNATIONAL PATENT APPLICATION NO. GB 9201570
SA 63869**

This annex lists the patent family members relating to the patent documents cited in the above-mentioned international search report. The members are as contained in the European Patent Office EDP file on
The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information. 25/11/92

| Patent document cited in search report | Publication date | Patent family member(s) | Publication date |
|---|---------------------|----------------------------|---------------------|
| EP-A-0375091 | 27-06-90 | DE-A- 3843628 | 05-07-90 |
| | | CA-A- 2007091 | 21-06-90 |
| | | JP-A- 2283275 | 20-11-90 |
| ----- | | | |
| WO-A-9011770 | 18-10-90 | CA-A- 2030779 | 12-10-90 |
| | | EP-A- 0425616 | 08-05-91 |
| ----- | | | |

EPO FORM P0479

For more details about this annex : see Official Journal of the European Patent Office, No. 12/82

THIS PAGE BLANK (USPTO)